Genetic Approaches for the Diagnosis and Treatment of Congenital Tooth Agenesis by Bonds, John Carless
  
 
 
GENETIC APPROACHES FOR THE DIAGNOSIS AND TREATMENT OF 
CONGENITAL TOOTH AGENESIS 
 
 
A Dissertation 
by 
JOHN C. BONDS  
 
Submitted to the Office of Graduate and Professional Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
Chair of Committee,  Gabriele Mues 
Committee Members, Rena D’Souza 
 Kathy Svoboda 
 Chunlin Qin 
 Jerry Feng 
Head of Department, Paul Dechow 
 
August 2014 
 
Major Subject: Biomedical Sciences 
 
 
Copyright 2014 John C. Bonds
 ii 
 
ABSTRACT 
 
Congenital tooth agenesis is the most common developmental anomaly in man. 
More severe forms of tooth agenesis (> 5 missing teeth) demand lengthy and expensive 
treatment approaches such as bone augmentation surgeries and placement of multiple 
implants. Tooth agenesis is caused by mutations in genes responsible for early tooth 
development; and ever since it had been shown that timely injections of functional 
recombinant gene products can overcome the corresponding, mutation-based 
developmental disorder, such new therapeutic strategies for the prevention of tooth 
agenesis should be attempted.  
In this research project I have pursued two objectives:  
1.) Basic research into the molecular genetics and therapeutics of the tooth 
agenesis gene PAX9. Since PAX9 is an intra-cellular transcription factor which cannot 
be replaced directly, suitable downstream targets for therapy have to be identified by 
comparing wild type and Pax9 deficient tooth organs. 
2.) Clinically oriented research into the molecular diagnostics of human tooth 
agenesis. We use candidate gene sequencing in large numbers of people with tooth 
agenesis to identify the majority of human tooth agenesis genes and to determine the 
molecular cause of tooth agenesis in individuals. 
In the first study I identify the genes and pathways that are affected by Pax9 
deficiency using microarray and q-PCR technology, and find that the Fgf, Shh and Wnt 
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pathways are more affected than Bmp4 which had previously been considered the main 
target of Pax9 in tooth development. 
The next study shows that it is possible to apply therapeutic approaches to 
unravel the complexity of molecular signaling within the developing craniofacial 
complex. Using small molecule Wnt therapies we are able to rescue palatal clefting in 
Pax9-deficient mice. 
Our third study presents a clinical aspect of human molecular genetics where we 
establish that tooth agenesis does not predispose women to ovarian cancer, as had been 
previously suggested. 
The last study shows that mutations in WNT10A, but not in WNT10B or WNT6, 
are highly prevalent in populations with tooth agenesis. We also suggest that there must 
be some kind of heterozygous advantage to retaining mutations in Wnt10a. However, 
that advantage has not been identified. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
OVERVIEW 
Teeth, like all other organs of the body, are formed and maintained as the result 
of temporally and spatially organized expression patterns of genes (Vaahtokari et al., 
1996). Disruption of this process results in tooth agenesis, the congenital absence of one 
or more permanent teeth, which is the most common inherited disorder in humans, 
affecting up to 10% of the population even when third molars are excluded (Mattheeuws 
et al., 2004; Shapiro and Farrington, 1983). Third molar agenesis is the most common 
with an incidence of 20% (JM, 1956; Lavelle et al., 1970); but it is usually disregarded 
in the missing tooth count and does not require any intervention.   
Traditionally, tooth agenesis can be separated into three main categories: a small 
number (1 to 5) of congenitally missing teeth is commonly referred to as hypodontia and 
consists typically of missing mandibular second premolars or maxillary lateral incisors 
with a prevalence of 3-4% and 2%, respectively. Many cases of this form of tooth 
agenesis may be satisfactorily treated with conventional dentistry. Missing greater than 5 
teeth is termed oligodontia and is less common with a prevalence of about 0.1%. A much 
rarer occurrence of congenitally missing all teeth is known as anodontia. Oligodontia 
and anodontia patients would greatly benefit from innovative approaches.   
Tooth agenesis can arise as an isolated trait and is then also referred to as 
selective or non-syndromic; or tooth agenesis can present as part of a syndrome. The 
 2 
 
syndromic form of tooth agenesis most often affects additional ectodermal appendages 
such as hair, nails, glands, and the skin itself. Both syndromic and non-syndromic tooth 
agenesis normally fall within the hypodontia or oligodontia category (Kapadia et al., 
2007; Nieminen, 2009). Although tooth agenesis does not present a life-threatening 
condition, it has a significant and long-term effect on oral health and well-being because 
it affects mastication, speech, and esthetic appearances for patients. Current treatment 
protocols for patients with tooth agenesis can impose significant functional, emotional 
and financial burdens on patients and their families and includes not only orthodontic 
and conventional procedures, but also expensive therapies such as bone augmentation 
surgeries and the placement of multiple implants, the latter of which can result in peri-
implantitis in 20% of patients or may not integrate into the bone resulting in implant and 
possible bone loss (Callan, 2007; Mombelli et al., 2012). Restorative features such as 
fixed partial dentures (bridges), crowns, or removable partial dentures have been shown 
to be sufficient for long-term use (Bartlett, 2007), however these are not without their 
negative outcomes as well. 
The obvious best approach for treating tooth agenesis patients would be 
prevention based on knowledge about the genetic origin of the disorder. Understanding 
the molecular genetics will most likely play an important role in the diagnosis, 
prognosis, and treatment of dental disorders such as caries, periodontal disease, 
mineralization defects, and especially tooth agenesis as it already does in the medical 
field. A thorough understanding on the molecular level would allow researchers to find 
suitable targets for supplementation with exogenous proteins or for modification by 
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pharmacologically active small chemicals. Since most tooth agenesis-causing gene 
mutations lead to haploinsufficiency, a small increase in active gene product can make a 
big difference in outcome (Das et al., 2002). Also, the permanent dentition is much more 
frequently affected than the primary dentition, which would probably allow for 
recombinant protein (or small molecule drug) replacement therapy after birth, perhaps 
even in the form of a local instead of systemic application. The successful use of 
recombinant Ectodysplasin-A (EDA) protein to prevent ectodermal dysplasia symptoms 
including tooth agenesis in affected mice and dogs has proven that such a molecular 
genetics approach is indeed feasible. The molecular interactions during development are 
so complex and difficult to dissect that it may be more revealing to make informed 
guesses and test directly using suspected gene products in experimental animals. 
In the following research project I pursued a molecular genetics approach 
towards the diagnosis of human tooth agenesis and possible treatment options of tooth 
agenesis caused by PAX9 mutations. 
 
THE MOLECULAR GENETICS OF PAX9 DEFICIENCY  
One focus of this research project is on the function of the transcription factor 
Pax9, specifically the exploration of the molecular mechanisms that lead to tooth 
developmental arrest resulting from Pax9 deficiency. Pax9 is a member of the Pax 
(paired box) gene family that contains a paired type homeodomain with DNA binding 
properties (Neubuser et al., 1995; Wang et al., 2009b). In humans, a severe tooth 
agenesis phenotype can be caused by the mutation of just one PAX9 allele (Stockton et 
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al., 2000) and since the disorder is transmitted as an autosomal dominant trait with a 
50% chance of transmission, affected members are fairly common in families with a 
Pax9 mutation (Goldenberg et al., 2000). In mice, both copies of the Pax9 gene have to 
be disabled to produce a tooth agenesis phenotype and the affected embryos also suffer 
from cleft palate, polydactyly, lack of thymus and parathyroid glands, and postnatal 
death. 
 
Pax9 expression during the different stages of tooth development 
Embryonic tooth development is a continuous process but is usually divided into 
several stages, each representing specific attributes and signaling events between the 
odontogenic epithelial and mesenchymal tissue layers. In mice (and also in humans), 
Pax9 is expressed very early in the presumptive tooth mesenchyme independent from 
epithelial signals around embryonic day E11.5, after the formation of the dental lamina 
around the dental placode stage. Mechanical compaction of mesenchymal cells may be 
the driving force for the initiation of Pax9 expression (Mammoto and Ingber, 2010).  
Pax9 expression becomes stronger during the next stage of tooth development, 
the bud stage. This stage is characterized by the advancement of the lamina/placode into 
the underlying mesenchyme of the first branchial arch (Thesleff, 2006) and the shift of 
odontogenic potential from the dental epithelium to the dental mesenchyme. During this 
process, mesenchymal cells gather around the tooth bud and form the dental papilla, 
which later will differentiate into the tooth pulp and dentin-secreting odontoblasts 
(Kollar and Baird, 1970).  
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Pax9 continues to be expressed in dental mesenchyme when the bud stage 
progresses into the cap stage at E14.5 and the enamel knot begins to form (Thesleff et 
al., 2001). Mesenchymally expressed gene products are involved in the induction of the 
enamel knot, which acts as a transient signaling center in the tooth epithelium and 
further drives the morphogenesis of the crown of the tooth (Aberg et al., 1997).  
With Pax9 deficiency the advancement from the bud to the cap stage does not 
occur and the tooth does not form.  
 
Pax9 function during tooth development 
Pax9 is a paired box transcription factor and its main task is the regulation of 
expression of other genes in the dental mesenchyme. Studies in knockout mice (Peters et 
al., 1998b) have revealed by in situ hybridization that Pax9 deficiency causes down-
regulation of Msx1, another homeodomain transcription factor, which occasionally can 
also act as a transcriptional repressor. Also down-regulated are lymphoid enhancer factor 
1 (Lef1) and the Tgfβ family member bone morphogenic protein 4 (Bmp4). Lef1 is a 
transcription factor in the Wnt pathway and is important in the dental epithelium, but 
less so in the mesenchyme. Bmp4 on the other hand has been considered the most 
important signaling factor for the progression of tooth morphogenesis, therefore the 
main function of Pax9 was thought to be the transcriptional activation of mesenchymal 
Bmp4. 
In vitro investigations showed that Pax9 can activate a proximal Bmp4 promoter 
fragment, strengthening this hypothesis. In these experiments it was shown that Msx1 
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could potentiate the activity of Pax9 on the Bmp4 promoter, although it could not 
activate the promoter by itself (Ogawa et al., 2006). The conclusion was that Pax9 and 
Msx1 form a positive feedback loop for activation of mesenchymal Bmp4. Tooth 
development arrest in Pax9- and also in Msx1-deficient individuals was caused by the 
lack of Bmp4. 
However, some doubt arose about this theory when it was shown that tooth 
agenesis-causing Msx1 mutations do not ameliorate the in vitro Bmp4 activation (Kong 
et al., 2011; Wang et al., 2011). Later it was also shown that some tooth types develop 
without any mesenchymal Bmp4 (Jia et al., 2013). 
One goal of this project is to better understand the role of Pax9 during tooth 
development and to gain more insight into its downstream signaling targets. Because 
mutations in Pax9 can cause severe agenesis of posterior teeth, they are a desirable target 
for molecular therapies which can be tested in Pax9-deficient mice. Since Pax9 is an 
intracellular transcription factor, which cannot be replaced directly, suitable targets for 
therapy must be sought after among the downstream effector genes of Pax9.  
 
THE CLINICAL GENETICS OF TOOTH AGENESIS 
Another goal of my project is to identify the known genes or even find new genes 
responsible for tooth agenesis in individual patients. There are currently only six genes 
(MSX1, AXIN2, EDA, EDAR, EDARADD, and WNT10A) other than PAX9 that cause 
selective (non-syndromic) tooth agenesis in humans. All seven together account for 
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about half of all cases worldwide. The causative genes for the other half remain to be 
determined. 
 
Known tooth agenesis genes 
Most of these genes have been identified studying large tooth agenesis families 
with linkage analysis and gene sequencing. 
 
EDA Pathway (EDA, EDAR, EDARADD; X-linked detected in 1996 (Kere et al., 
1996); Selective discovered in 2006 (Tao et al., 2006)) 
Mutations in Ectodysplasin A (EDA) cause X-linked hypohidrotic ectodermal 
dysplasia (XHED) or selective tooth agenesis (STHAGX1). Males are strongly affected, 
females are not or only mildly affected. Different sets of mutations cause either the 
XHED syndrome or the non-syndromic tooth agenesis.  
EDA pathway genes Ectodysplasin-A receptor (EDAR) and EDAR-associated 
death domain (EDARADD) also cause HED, which is often autosomal recessive or they 
cause selective tooth agenesis, which is present in about 50% of heterozygotes. Primary 
and permanent dentitions are both affected, with a predilection for incisor agenesis. 
Perinatal treatment with recombinant EDA protein is curative in mice and dogs with 
EDA mutations. Clinical trials have started to test the efficacy of this protein in humans 
with EDA mutations as well. Testing hypodontia patients for EDA mutations may 
become mandatory in the near future.  
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MSX1 (detected in 1996 (Vastardis et al., 1996)) 
Msx1 is a homeodomain transcription factor which can inhibit or activate 
transcription. It is expressed in tooth bud mesenchyme as well as in the developing heart, 
limb, and other craniofacial tissue. Inheritance of MSX1-associated phenotypes is 
autosomal dominant – a mutation in one allele is sufficient to cause tooth agenesis in 
humans. MSX1 mutations affect only the permanent human dentition. Mice, which have 
only one dentition, require the loss of both Msx1 alleles to develop a missing tooth 
phenotype. Humans with mutations in Msx1 normally fail to develop premolars and 
third molars (Kim et al., 2006) and these mutations are normally located in the 
homeodomain. 
MSX1 mutations can also be found in cleft lip/palate patients and Witkop 
syndrome.  
 
PAX9 (detected in 2000 (Stockton et al., 2000)) 
PAX9 encodes a paired box transcription factor expressed in tooth bud 
mesenchyme, thymus, parathyroid glands, and limb buds. In vitro, PAX9 cooperates 
with MSX1 to induce BMP4, a key signaling factor in tooth development.–The mutation 
of one PAX9 allele is sufficient to cause tooth agenesis in humans with autosomal 
dominant inheritance. Most PAX9 mutations affect the permanent dentition while some 
affect both primary and permanent dentitions. Molars are the predominantly missing 
tooth group followed by premolars and in rare cases incisors. Functional studies have 
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shown that loss of DNA-binding is the most common cause for dysfunction of mutant 
proteins (Wang et al., 2009b). 
 
AXIN2 (detected in 2004 (Lammi et al., 2004)). 
AXIN2 is an inhibitor in the Wnt pathway. The colon cancer gene APC 
(adenomatous polyposis coli) is part of the same pathway. AXIN2-caused hypodontia 
has been found in 6 independent cases. AXIN2 mutations cause mild to severe tooth 
agenesis with a mixed distribution pattern. In one family with AXIN2 mutation  
oligodontiawas inherited together with a predisposition for colon cancer, therefore all 
patients with severe mixed tooth agenesis should be tested for AXIN2 mutations. 
 
WNT10A (detected as selective tooth agenesis gene in 2009 (Bohring et al., 2009) and 
in 2012 (van den Boogaard et al., 2012)). 
WNT10A is in the Wnt family of signaling factors that play major roles in 
development and oncogenesis. WNT10A mutations have a very high prevalence in 
human tooth agenesis  (van den Boogaard et al., 2012). They can also cause ectodermal 
dysplasia syndromes and in fact WNT10A was initially discovered as the cause of the 
rare Odonto-onycho-dermal dysplasia (Adaimy et al., 2007) and Schopf-Schulz-Passarge 
syndromes (Nagy et al., 2010). 
Heterozygous and homozygous mutations cause mild or severe tooth agenesis 
phenotypes, respectively. The phenotype is similar to the EDA phenotype with incisors 
being affected in mild forms while a mixed agenesis pattern is seen in severe forms. 
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Surprisingly, one single mutation (Phe228Ile) is the cause of most cases in European 
populations. 
  
Suspected tooth agenesis genes 
BMP4, MSX2, and PITX2 mutations have been found in single patients with 
relatively mild tooth agenesis (own observations and (Huang et al., 2013)). 
 
Detection of new tooth agenesis genes 
Linkage analysis, the classical method for finding causative genes for genetic 
disorders, requires large families with many affected individuals. Such large families 
have become rare in Western societies and we will have to approach gene identification 
using new means. The latest approach is exome sequencing which is perfectly suited for 
the detection of the genetic cause of rare, apparently genetic, disorders even when a 
large family is not available. However, at this point this method is still expensive and not 
suitable for large-scale screening applications. 
In principle, all genes that are expressed during tooth development are candidates 
for investigation in patients with tooth agenesis. However, some of these genes are more 
likely candidates than others. For example, genes that also cause tooth agenesis in 
knockout mice or genes that are downstream of a known tooth agenesis gene, like the 
downstream genes EDAR and EDARADD in the EDA pathway or genes that cause 
syndromic tooth agenesis such as EDA and WNT10A, are more likely to be candidate 
genes for selective tooth agenesis. 
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For large-scale mutation screening of tooth agenesis samples, a candidate gene 
approach with direct sequencing of dozens of independent samples is still a useful 
approach. 
 Because I am pursuing a DDS/PhD degree, I have engaged in both basic science 
and clinical research around the common theme of diagnosis and future therapy of tooth 
agenesis. This project reflects both aspects of scientific research which was tailored to 
provide me with a more rounded scientific training.  
 
SUMMARY  
 The two objectives of my research are:  
1) Basic research into the molecular genetics and therapeutics of the tooth agenesis 
gene Pax9.  
Mutations in this gene can cause severe agenesis of posterior teeth and are 
therefore a desirable target for molecular therapies which can be tested in Pax9 deficient 
mice. Since Pax9 is an intracellular transcription factor which cannot be replaced 
directly, suitable targets for therapy have to be identified among downstream effector 
genes of Pax9.  
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2) Clinical approaches to study and diagnose the genetic causes of tooth agenesis in 
human populations.  
In order to provide as many tooth agenesis patients as possible with the new 
therapies it is mandatory to find as many human tooth agenesis genes as possible. This 
can be done by candidate gene sequencing in large numbers of people with tooth 
agenesis. Candidate gene sequencing is also used for the molecular diagnosis of tooth 
agenesis in individual families. 
Chapter II of this dissertation presents a basic science approach to understanding 
the downstream effects of Pax9. Using microarray technology and quantitative PCR we 
identify the genes and pathways affected by Pax9 deficiency. 
Chapter III provides evidence that an informed guess about important Pax9 target 
genes as derived from the results in Chapter II can lead to useful choices for replacement 
therapies. Using replacement therapies we show that we are able to rescue palatal 
clefting in Pax9-deficient mice. 
Chapter IV presents a clinical aspect of human molecular diagnostics where we 
establish that tooth agenesis is not likely to predispose women to ovarian cancer, as had 
been previously suggested. 
Chapter V is a study about the prevalence of Wnt10a, Wnt10b and Wnt6 in 
populations with tooth agenesis.  
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CHAPTER II  
PAX9 DEFICIENCY IN TOOTH DEVELOPMENT AFFECTS MULTIPLE GENETIC 
PATHWAYS OTHER THAN BMP4 
 
SYNOPSIS 
The molecular mechanisms involved in tooth development have been thoroughly 
studied in recent years, leading to the discovery of all the major signaling pathways that 
contribute to tooth formation.  However, many details are still missing about the exact 
role of genes that, when mutated, are associated with human tooth agenesis. Deficiency 
of PAX9, a paired domain transcription factor in tooth bud mesenchyme, leads to 
congenitally missing teeth in both humans and mice which could be partly attributed to 
the down-regulation of Bmp4, a signaling factor required for several critical steps in 
tooth development. To learn more about the activities of the Pax9 protein, we studied 
Pax9-dependent gene expression levels in the developing murine tooth using microarray 
and quantitative PCR.  Our findings suggest that Bmp4 activation may not be the most 
prevalent activity of Pax9 since Bmp4 showed only modest down-regulation in Pax9-
deficient tooth anlagen when compared to other signaling and transcription factors such 
as Fgf, Shh, Tcfap2, Foxf1, Egr, and several others.  
 
INTRODUCTION     
Tooth development has been studied since the late 1930’s, but only in the last 
twenty years have many of the underlying molecular mechanisms been discovered, 
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notably the transcription factors and signaling pathways that are the primary driving 
forces responsible for this process which involves reciprocal genetic interactions 
between epithelial and mesenchymal layers of the dental lamina.  Other studies 
(Mammoto and Ingber, 2010) have shown that mechanical forces induced by 
condensation and cell compaction also play a role in tooth formation by directly 
activating the expression of genes, such as the paired domain transcription factor Pax9 in 
tooth bud mesenchyme. 
In mice, the Pax9 gene is prominently expressed in the mesenchymal layer of the 
early tooth anlage. Lack of Pax9 expression leads not only to tooth agenesis, but also to 
missing thymus and parathyroid glands, cleft secondary palate, and supernumerary digits 
of the hind limb (Peters et al., 1998b). In situ hybridization studies with Pax9 knockout 
mice revealed a decreased expression of homeodomain transcription 
factor/transcriptional suppressor Msx1, Tgfβ-related signaling factor Bmp4, and Wnt 
pathway transcription factor Lef1 in tooth bud mesenchyme.  Bmp4 had been previously 
identified as an important signaling factor in tooth development and thus the reduction of 
Bmp4 expression was considered the most likely cause of the tooth agenesis seen in 
Pax9-deficient mice and humans.  This notion was strengthened by in vitro 
investigations suggesting that Pax9 can activate both Msx1 and Bmp4 promoters and 
that Msx1 cooperates with Pax9 to induce Bmp4 expression in tooth organ mesenchyme 
although Msx1 by itself cannot activate the Bmp4 promoter (Ogawa et al., 2006). 
However, later studies suggested that mesenchymal expression of Bmp4 requires 
additional factors besides Pax9 and Msx1 and that Pax9 and Msx1 may contribute to the 
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activation of regulatory networks other than the Bmp4 signaling pathway (Nakatomi et 
al., 2010; Zhao et al., 2008; Zhou et al., 2011). Therefore, we hypothesized that Pax9 
and Msx1 do not regulate Bmp4 to the extent previously thought, and that Bmp4 down-
regulation may contribute, but not be the central component that leads to tooth agenesis 
in Pax9-deficient tooth germs.  
Knowledge about the main downstream targets of Pax9 in tooth development is 
central for the discovery of new therapeutic approaches for the prevention of tooth 
agenesis in humans, which is caused by haploinsufficiency of Pax9 and presents with 
severe agenesis of predominantly posterior teeth. Ever since it had been shown that a 
few, well-timed injections of recombinant ectodysplasin A can rescue hair, gland and 
tooth formation in animals with ectodermal dysplasia (Gaide and Schneider, 2003), this 
“missing protein replacement” approach has become a potentially viable alternative to 
current tooth replacement therapies. Since the intracellular transcription factor Pax9 
cannot easily be replaced, substitution of downstream extracellular targets of Pax9 will 
be necessary to overcome developmental arrest of the tooth germ. Alternatively, small 
molecule chemicals with the property of pathway activators or inhibitors could be 
employed once the critical downstream pathways have been discovered.   
In this study we evaluated gene expression differences between Pax9-deficient 
and wild-type (WT) embryonic tooth anlagen of mice using expression microarrays and 
quantitative PCR to uncover new downstream effector genes of Pax9 in the developing 
tooth.  
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MATERIALS AND METHODS     
Mouse line 
We used a C57/B6 mouse strain in which the first exon and half of the second 
exon of Pax9 was replaced by an FRT-flanked neo expression cassette followed by Myc-
Osr2 cDNA segment, referred to as Pax9-/-. This strain was kindly provide by Dr. 
Rulang Jiang, Cincinnati’s Children’s Hospital, and was shown to be functionally Pax9-
null in homozygous embryos.  Since homozygotes (Pax9-/-) die at birth, heterozygous 
(Pax9+/-) mice were mated and embryos from multiple litters were harvested at either 
embryonic day E13.5 and E14.5 according to IACUC standards. Immediately after 
harvesting, mandibular 1st molar tooth anlagen were micro-dissected using a stereo 
microscope and stored separately in RNAlater (Ambion).  After genotyping, RNA 
extraction was performed on these tissues using an RNeasy Mini Kit (Qiagen). Tooth 
bud RNA from 15-20 homozygous (Pax9-/-) embryos and from a similar number of wild-
type littermates was pooled separately and stored at -800C.  
 
Data acquisition/analysis 
Expression microarrays were performed by the UT Southwestern Medical Center 
microarray core facility and included Whole Mouse Genome 430 2.0 arrays and a Mouse 
Exon 1.0 ST array (Affymetrix).  For the Whole Genome array the statistical analysis, 
performed by Ingenuity’s iReport, identified 73 significantly differentially expressed 
genes (DEGs) (I think that there were more in Hannah’s 430 and exon arrays and the 
E13.5 array – Hanna’s exon array showed 74, her 430 array showed 176; mine was 179; 
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this number was obtained using the iReport software, not looking at fold change in 
particular. We can change to say that we identified DEGs as having a fold change 
greater than 1.5 instead) out of approximately 39,000 transcripts (representing about 
14,000 different genes) with a fold change cutoff value of 1.5 or greater. The Whole 
Mouse Genome array DEGs were clustered based on molecular function.  From all the 
genes affected by Pax9 deficiency, known mesenchymal transcription regulators and 
signaling molecules were chosen as the most important candidates for further analysis, 
followed by epithelially expressed genes with large expression differences. Genes with 
poorly understood function were also chosen as candidate genes if they showed large 
expression differences between Pax9-/- and wild-type. The localization of the transcripts 
of these DEGs were determined using the Eurexpress database: “A Transcriptome Atlas 
Database for Mouse Embryo” that uses in situ hybridization on sagittal sections of E14.5 
mouse embryos to depict the expression pattern of most genes down to the single cell 
level (Diez-Roux et al., 2011).  
 
Real-time quantitative PCR 
RNA was quantified with a Nanodrop spectrophotometer (Thermo), and equal 
amounts of Pax9-/- and WT RNA were used.  Two step Reverse Transcriptase 
quantitative PCR (RT-qPCR) was performed using the GoScript Reverse Transcription 
System (Promega) with both random and oligo(dT) primers and GoTaq qPCR Master 
Mix (Promega).   cDNA was prepared from total RNA using wild-type versus Pax9-/- 
mouse tooth organ tissue.  RT-qPCR was performed following Minimum Information 
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for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidlelines. 
Technical replicates were performed in triplicate using Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as the chosen housekeeping gene. We compared expression 
levels of genes between the two groups.  RT-qPCR and data analysis was performed 
using a C1000 thermocycler with a CFX96 optical reaction module (Bio-Rad).  Primers 
for the DEGs of interest are as follows:  Adi1 forward primer, 5’-CGG AGT GCT CTA 
TTG GAA GC-3’ and reverse primer, 5’-TCC TCC TTG TCC CTG ACA TC-3’; Bmp4 
forward primer, 5’-GGA AGG CAA GAG CGC GAG GC-3’, and reverse primer, 5’-
GTG CGT CGC TCC GAA TGG CA-3’; C1qtnf3 forward primer, 5’-CTC CAC AAG 
CTG GAG GAC TG-3’, and reverse primer, 5’-TCC CAT TGT TTC CAT GGT TT-3’; 
Daam1 forward primer, 5’-GAA CAC AAG CAT GAG CTG GA-3’, and reverse 
primer, 5’-AAC ACC TCC TCA GAG CCA GA-3’; Dkk1 forward primer, 5’-TAT 
GAG GGC GGG AAC AAG TA-3’, and reverse primer, 5’-AGG AAA ATG GCT GTG 
GTC AG-3’;  E2f6 forward primer, 5’-CTG GGG GCA TTC TTG ACT TA-3’, and 
reverse primer, 5’-GAG TTC TGC CTG CAG CTT CT-3’; Fgf3 forward primer, 5’-
GCG CTA CCA AGT ACC ACC TC-3’, and reverse primer, 5’-GGC GGG AAG CAT 
ATG TAT TG-3’; Foxf1a forward primer, 5’-GGC CTC CTA CAT CAA GCA AC-3’, 
and reverse primer, 5’-CTG GGC GAC TGT GAG TGA TA-3’; Gapdh forward primer, 
5’-TTG ATG GCA ACA ATC TCC AC-3’, and reverse primer, 5’-CGT CCC GTA 
GAC AAA ATG GT-3’; Gstm6 forward primer, 5’-CCG GAC CTG TTC TCA GAC 
TC-3’, and reverse primer, 5’-CCC ATG GCG TAT CTC TTC TC-3’; Msx1 forward 
primer, 5’-CTC TCG GCC ATT TCT CAG TC-3’, and reverse primer, 5’-TAC TGC 
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TTC TGG CGG AAC TT-3’; Odam forward primer, 5’-AGC CAG ACC TCT CTC 
AGC AG-3’, and reverse primer, 5’-AAA TAG CTG CTG CCC TGT GT-3’; Osr2 
(exon1) forward primer, 5’-CAA CAC GCT CGC TCT TTA CA-3’, and reverse primer, 
5’-GCA CAG CTT GGA AAG GTC AT-3’; Osr2 (exons 2-3) forward primer, 5’-AGT 
TTT GCG GCA GAC ACT TT-3’, and reverse primer, 5’-TCC TTT CCC ACA CTC 
CTG AC-3’; Pax9 forward primer, 5’-CCA AGG GCA ACA GTC ACC-3’, and reverse 
primer, 5’-GGC GGC TCA GTC TAT CAC TC-3’; Shh forward primer, 5’-GCC ATC 
TCT GTG ATG AAC CA-3’, and reverse primer, 5’-CCA CGG AGT TCT CTG CTT 
TC-3’; Tfap2b forward primer, 5’-CCA AGA AGT GGG CTC AGA AG-3’, and reverse 
primer, 5’-TGG CAT CTT CAA CTG ACT GC-3’; Trp63 forward primer, 5’-TTT GAT 
GCC CTC TCT CCA TC-3’, and reverse primer, 5’-CTT CGC AAT CTG GCA GTA 
CA-3’. 
 
RESULTS   
In this study we investigated the Pax9-dependent gene expression pattern in 
mouse embryonic day 14.5 (E14.5) tooth organs and their surrounding mesenchymal 
layer by microarray in order to obtain the overall pattern of gene expression changes 
around the time of developmental arrest (Table 2-1). We chose to pool tooth bud RNA 
from 20 to 30 embryos from different litters for each array to avoid sampling bias and 
the need for cDNA amplifications. Also, although Pax9 is only expressed in the 
mesenchymal layer of the tooth bud, we chose to isolate whole tooth bud RNA from 
mandibular first molars for our arrays instead of separating the mesenchymal from the 
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epithelial layer which could have resulted in greater loss or degradation of material. We 
adopted this strategy because the spatiotemporal expression pattern of the majority of 
potential target genes was either well-known or verifiable by consulting the Eurexpress 
data base and because we were interested in exploring indirect targets of Pax9 as well as 
direct ones since both are potentially suitable targets for replacement therapies. We 
confirmed our E14.5 results using RT-qPCR (Figure 2-1) and followed up our analysis 
with arrays using E13.5 tooth bud RNA, which were added later for the assessment of 
temporal changes in expression patterns (Figure 2-2). 
Our results suggest that Pax9 has a direct or indirect impact on the up- and down-
regulation of many diverse genes in the mesenchymal and sub-mesenchymal layer; in 
addition the differential expression of a large number of transcripts was detected in the 
epithelial layer and enamel knot, including several that had not been prominently 
associated with tooth formation. The array data were used mainly as a guide for the more 
accurate quantitation of expression differences by quantitative PCR.  
As expected, Pax9 levels were significantly decreased in Pax9-deficient tooth 
organ tissue, but surprisingly, the microarray and RT-qPCR data obtained from a 
comparison of Pax9-/- and wild-type tooth organs suggested that Bmp4 expression was 
less than 1.5 fold down-regulated by Pax9 deficiency at both E13.5 and E14.5. Bmp4 did 
not even once appear as a significantly differentially expressed gene in any of the four 
arrays even if a cut-off value of 1.3 fold expression difference was chosen; and only 
rarely was a larger expression difference encountered in RT-qPCR investigations of 
Pax9-deficient and wild-type cDNAs. 
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Instead, several other genes showed more impressive differential regulation; 
among these were a few signaling factors such as mesenchymally expressed fibroblast 
growth factor 3 (Fgf3) along with Fgf4, Fgf20, Lymphotoxin B (Ltb) and sonic 
hedgehog (Shh), which are expressed in the epithelial enamel knot signaling center. In 
fact, Shh was the most strongly down-regulated gene in the E14.5 arrays; but it may not 
be the sole cause of the tooth developmental arrest because Shh mutations in humans are 
not associated with absence of posterior teeth like seen in Pax9 deficiency; instead they 
feature a solitary, upper central incisor (Roessler et al., 1996). The exact molecular 
mechanism of Shh expression dependence on Pax9 is not yet clear, but probably 
involves Fgf and Wnt pathways. Fgf3 and Fgf4, which are strongly down-regulated in 
Pax9
-/- tooth buds at E14.5 have previously been shown to be dependent on epithelial 
Wnt signaling and their lack of expression in Lef1-/- mice was associated with strongly 
reduced Shh expression in the enamel knot (Kratochwil et al., 2002). Notably in humans, 
Fgf3 mutations are associated with microtia and microdontia (Alsmadi et al., 2009); 
furthermore association studies have implied a connection between the Fgf3 gene and 
tooth agenesis (Kuchler et al., 2013). Fgf and Shh pathway components should be 
amenable to substitution therapies as a potential future treatment for PAX9-associated 
tooth agenesis. 
Also significantly differentially expressed were many transcription factors such 
as early growth response 3 (Egr3), transcription factor ap2 (Tcfap2), odd skipped related 
2 (Osr2), distal-less 2 (Dlx2), lymphoid enhancer factor 1 (Lef1), Sp6, forkhead box f1a 
(Foxf1a), t-box transcription factor 1 (Tbx1), paired-like homeodomain transcription 
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factor 2 (Pitx2) and others. Receptors, signal transduction proteins, structural proteins 
and pathway inhibitors were affected as well. Among the transcription factors, Tcfap2b 
was found to be one of the more strongly down regulated genes at both E13.5 and E14.5 
in Pax9-/- mice where it is strongly and exclusively expressed in molar dental 
mesenchyme. Tcfap2b is a member of the AP2 family of transcription factors that are 
involved in many developmental processes. Mutations in Tcfap2b are responsible for 
Char syndrome (Satoda et al., 2000), which is a condition that affects the development of 
the face including teeth, heart, and limbs.  Egr3, which is also strongly and fairly 
exclusively expressed in tooth bud mesenchyme at E14.5, is substantially down-
regulated; but nothing is currently known about its functional significance in tooth 
development. Several Keratin transcripts, most significantly Krt17, were down 
regulated. 
The results for Osr2 were at first confusing because, contrary to expectation, it 
was up-regulated in the array obtained with Pax9-/- tooth bud RNA. This led to our 
suspicion that the Osr2 transgene which was inserted into the Pax9 locus and can be 
transcribed but not translated into protein, may have been responsible for this outcome. 
Indeed, when we performed RT-qPCR using primers to amplify the part of the Osr2 
cDNA not present in the transgene insert, we could show that the expression of 
endogenous Osr2 was actually down-regulated by more than 3-fold. 
Of the inhibitors that affect the Wnt and Bmp4 pathways, Sostdc1, Dkk4, Sfrp4 
and Apcdd1 are down-regulated while Dkk1 and Chrdl1 show modest up-regulation at 
E14.5 (Ahn et al., 2010; Fedi et al., 1999; Hsieh et al., 1999; Leyns et al., 1997; Sakuta 
 23 
 
et al., 2001), suggesting that Pax9 may have a role in fine-tuning Wnt-induced activation 
of the morphogenetic process; possibly to allow for mesenchymal growth before final 
differentiation. Some of these extracellular pathway inhibitors may also be useful for 
replacement therapies.  
Several of the differentially expressed genes were found in the sub-mesenchymal 
layer (C1qtnf3, Sfrp4, and others), indicating that the activities of Pax9 are not limited to 
the tooth bud but may include supporting structures. 
 
DISCUSSION     
Human trials for the substitution of recombinant EDA for a curative treatment of 
hypohidrotic ectodermal dysplasia, including its associated tooth agenesis have started. 
These trials were born from experiments with EDA deficient mice and dogs which 
showed that treating affected embryos via maternal injection or the affected newborn 
mice and dog pups with recombinant Eda could prevent the phenotypic effects of the 
gene mutation (Gaide and Schneider, 2003). This success inspired the pursuit of similar 
approaches for the treatment of other genetically linked developmental disorders.  
Pax9 deficiency causes tooth developmental arrest at bud stage in both humans 
and mice, yet the molecular mechanisms that lead to this defective phenotype have 
remained poorly understood.  We pursued this knowledge gap with microarray studies 
from murine embryonic tooth organs.  Only around 200 genes were shown to be 
differentially expressed greater than 1.5 fold. Using bioinformatics approaches and real-
time quantitative PCR we narrowed our results to even fewer genes in which we were 
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confident were differentially expressed and also located in the developing tooth organ 
region.   
Unexpectedly Bmp4 expression was not significantly altered in our study of 
Pax9-deficient tooth buds versus wild-type tooth buds. This result requires careful 
scrutiny since it does not agree with prior investigations. In wild-type mice, Bmp4 had 
been repeatedly shown by in situ hybridization to be prominently expressed in tooth bud 
mesenchyme at E13.5 and E14.5; at E14.5 Bmp4 was shown to be additionally 
expressed in the emerging enamel knot signaling center in tooth bud epithelium. In 
Pax9-deficient mice, however, Bmp4 was reported to be neither detectable in the 
mesenchymal nor in the epithelial layer by in situ hybridization. Therefore we had 
expected a significant difference of Bmp4 expression in our RNA samples from E14.5 
WT and Pax9-deficient whole tooth germs but to our disappointment this was not the 
case. We did not observe a similar discrepancy between previously reported in situ 
hybridization results and our array or qPCR data with respect to Msx1, Lef1, Osr2, Shh 
and Fgfs. At the present it is not clear what caused this disagreement; to our support it 
should be noted that it has also been shown recently that Bmp4 expression in Msx1 
deficient mice is by far not as extensively down-regulated as had previously been 
assumed (our unpublished results and (Jia et al., 2013; O'Connell et al., 2012)). 
Since Bmp4 expression seems largely unchanged in Pax9-/- deficiency; a slight 
delay in developmental timing should have allowed for the accumulation of sufficient 
Bmp4 to proceed with tooth morphogenesis (Miletich et al., 2011). Bmp4 mutations in 
humans have been described to affect the development of eyes but not teeth; only one 
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paper (Huang et al., 2013) suggests that a Bmp4 prodomain mutation may be associated 
with relatively mild premolar agenesis. In summary, our data suggest that BMP4 is not 
the most important factor in the development of Pax9 related tooth agenesis. 
Endogenous Osr2  is significantly down regulated in Pax9-/- tooth bud tissue as 
expected, since it had been previously described that expression of Osr2 in tooth bud 
mesenchyme is dependent on Pax9 (Zhou et al., 2011). Osr2 however must be an 
inhibitor of tooth development because its removal leads to an additional row of teeth or 
to significant rescue of the normal row of teeth in mice lacking all mesenchymal Bmp4 
(Jia et al., 2013). Therefore the down regulation of Osr2 cannot be responsible for the 
tooth developmental arrest resulting from Pax9 deficiency. In contrast to the situation in 
Pax9-/- mice, experimental Osr2 down regulation in Msx1-/- tooth germs seems to restore 
tooth development (Zhang et al., 2009b). This demonstrates quite clearly that the 
complexity of gene regulatory events during tooth development requires further 
research. 
According to our results Shh and Fgf3 are the most strongly down-regulated 
genes at E14.5. Also substantially reduced is the expression of two other Fgf genes, Fgf4 
and Fgf20, that are well-known for their contribution to odontogenesis. Fgfs and Shh 
have been previously shown to be integrated into an epithelial-mesenchymal signaling 
loop which is initiated by epithelial Wnt signaling and mediated by Lef1, a transcription 
factor in the canonical Wnt pathway (Kratochwil et al., 2002). More specifically, this 
signaling loop probably starts with Wnt 10 (a or b) around bud stage leading to Lef1 
induced Fgf4 expression in the epithelial enamel knot area. Fgf4 then signals to the 
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dental mesenchyme resulting in mesenchymal Fgf3 activation which in turn is required 
for subsequent Shh expression in the enamel knot signaling center. This signaling loop is 
interrupted in Lef1 deficient mice leading to tooth developmental arrest at bud stage 
similar to the situation in Pax9-deficient mice.  In Lef1 deficiency, tooth development 
can be completely rescued by the application of Fgf4 (also Fgfs 7, 8a, 9 or 10) but not by 
application of Bmp4 or Shh. Our results suggest that Pax9 is somewhere involved in this 
Wnt-Fgf signaling loop. Additional support for this theory is provided by the finding that 
constitutional activation of Wnt signaling can override the Pax9-associated tooth 
developmental arrest leading to an abundance of irregular teeth (O'Connell et al., 2012). 
The importance of the Wnt pathway in odontogenesis is furthermore underscored by the 
fact that mutation in WNT10a appear to be the most common cause of human tooth 
agenesis (Bohring et al., 2009; Mues et al., 2014; van den Boogaard et al., 2012). 
The question now arises at which stage and how Pax9 becomes involved in this 
Wnt-Fgf-Shh signaling loop. Pax9 starts being expressed quite early (before E12) in the 
condensing mesenchyme and Fgf3 cannot be its most important target because selective 
Fgf3 deficiency leads only to smaller, not to missing teeth. Similarly, a reduction of Shh 
cannot be the sole cause of Pax9-associated tooth agenesis since human Shh mutations 
produce a much less severe and also different dental phenotype than Pax9, featuring 
only a solitary maxillary central incisor instead of the molar and premolar agenesis 
encountered in patients with PAX9 mutations (Das et al., 2002; Roessler et al., 1996). 
The modulation of some aspects of Wnt signaling itself may be another factor 
contributing to the Pax9-associated tooth agenesis. This can be inferred from the down-
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regulation of the Wnt pathway inhibitors Sostdc1, Dkk4, Sfrp4 and Apcdd1 and the up-
regulation of Dkk1 at E14.5. All these inhibitors show different expression profiles and 
only Dkk1 seems to be exclusively located in the dental mesenchyme. Dkk1 (Dickkopf-
related protein 1) is a potent Wnt antagonist and other studies have shown that over-
expression of Dkk1 in a 2.3-kb Col1a-Dkk1 transgenic mouse leads to malformed 
second molars and loss of third molars (Han et al., 2011). It would be of great interest to 
test the effect of these Wnt inhibitors on the craniofacial development of Pax9-deficient 
mouse embryos with or without the addition of Fgfs and Shh.  
Another important role of Pax9 (and especially Msx1) may be the promotion of 
mesenchymal growth, probably mediated by Fgfs like Fgf3 coupled with a delay of 
premature differentiation, which could be achieved through temporary global inhibition 
of epithelial Wnt signaling.  
Lately it is becoming apparent that mesenchymal Bmp4 activation is mainly 
achieved through Wnt signaling, but Pax9 and Msx1 may contribute slightly through 
positive regulation of mesenchymal Lef1 expression (Behrens et al., 1996). On the other 
hand, the importance of mesenchymal Bmp4 expression has been diminished by 
showing that its expression is not required to the extent previously thought (Jia et al., 
2013)- possibly a lack of mesenchymal Bmp4 can be compensated for by epithelial 
Bmp4.   
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CHAPTER III 
A BOOST IN WNT SIGNALING RESCUES PALATE FORMATION 
 
SYNOPSIS 
In this study, we found that a few maternal injections of a small molecule Wnt 
pathway activator prevents cleft palate formation in Pax9-/- mouse embryos without 
affecting other associated phenotypes such as tooth and thymus agenesis, or hind limb 
polydactyly.  No overt adverse effects of this treatment were detected in mother or 
normal littermates suggesting that small molecule signaling pathway modulators may be 
effective for the prevention of developmental abnormalities. 
 
INTRODUCTION 
Pax9 is a paired box transcription factor which is required for craniofacial, tooth, 
and limb development. Mice without a functional Pax9 gene die at birth and have a 
missing thymus, missing parathyroid glands, cleft secondary palate, tooth agenesis, and 
supernumerary digits of the hind limb while heterozygous mice are completely normal 
(Peters et al., 1998b). In humans only heterozygous pathogenic mutations have been 
found in the PAX9 gene, all of which cause severe non-syndromic tooth agenesis of 
mostly posterior teeth (Wang et al., 2009b). Concordantly, a possible association of the 
PAX9 gene with orofacial clefting (Ichikawa et al., 2006; Lee et al., 2012; Song et al., 
2013) in humans has also been described. 
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The molecular and pathophysiological mechanisms leading to cleft palate in 
Pax9-deficient mice have been reported to involve down-regulation of Bmp4, Fgf10, 
Shh and Osr2 resulting in malformed palatal shelves which fail to elevate, a defect which 
could be partially rescued by restoring Osr2 expression (Zhou et al., 2013). Pax9 has 
also been described to play a role in palatal fusion when studied in TGF-β3 null mice 
(Sasaki et al., 2007), however, others have shown that Pax9-deficient palates can fuse in 
vitro when placed next to each other suggesting that clefting is primarily due to lack of 
proper palate morphogenesis and elevation.    
In order to gain a better understanding about Pax9 target genes in tooth 
development, we previously evaluated the gene expression differences between Pax9-
deficient (Pax9-/-) and wild-type (Pax9+/+) mouse embryonic tooth bud tissue by 
expression microarray and qPCR analysis. Unexpectedly, among all the gene expression 
changes we found several genes involved in the Wnt signaling pathway, which had so 
far not been described as a Pax9 target although it had been shown that constitutively 
activated Wnt signaling can overcome the tooth developmental arrest in Pax9 deficient 
mice (O'Connell et al., 2012). 
 
MATERIALS AND METHODS 
To determine if the Wnt pathway does in fact play a role in the pathogenesis of 
the Pax9-/- phenotype we chose to modulate the Wnt pathway in vivo by injecting a small 
molecule Dickkopf-related protein 1 (Dkk1) inhibitor (Pelletier et al., 2009) (WAY-
262611, Enzo Life Sciences) into pregnant Pax9+/- mice which had been mated with 
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Pax9+/- males. Pax9-/- mice were kindly provided by Rulang Jiang and are previously 
described (Zhou et al., 2013). Briefly, the Pax9 locus contains a frt-flanked neo 
expression cassette followed by an unexpressed Myc-Osr2A cDNA cassette which 
replaces exon 2 of the Pax9 gene. Pax9-/- mice resulting from the mating of heterozygous 
parents of this strain display phenotypes identical to a previously described Pax9-
deficient mouse model (Peters et al., 1998b) such as missing teeth, cleft palate, thymus 
and parathyroid gland abnormalities, and hind limb polydactyly, all of which are 
completely penetrant. 
The drug used for increasing Wnt signaling, (1-(4-(naphthalen-2-yl)pyrimidin-2-
yl)piperidin-4-yl) methanamine, also known as WAY-262611, has been described 
previously (Pelletier et al., 2009) and was shown to potentiate the Wnt β-catenin cellular 
signaling pathway through the inhibition of the potent Wnt inhibitor Dkk1. WAY-
262611 was dissolved in DMSO and diluted 1:10 with PBS. Three consecutive doses of 
12.5 mg/kg were injected in the tail veins of Pax9+/- pregnant mice at embryonic days 
E12.5, E13.5 and E14.5 (n=15; 6 pregnant females with 15 homozygous recessive 
embryos total). The injection of vehicle (10% DMSO in PBS) alone at E12.5, E13.5 and 
E14.5 did not rescue palate formation in the Pax9-/- embryos (n=7; 3 pregnant females 
with 7 homozygous recessive embryos total). All mouse pups were inspected 
immediately after birth (P0) and their genotype was determined. The palate phenotype of 
the Pax9-/- pups was observed both visually with a stereo dissecting microscope and 
histologically using H&E staining. Wild type and heterozygous Pax9+/- littermates of the 
Pax9-/- pups as well as their mothers were observed for 12 weeks).   
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All experiments complied with all relevant institutional and national animal 
welfare laws, guidelines, and policies. 
 
RESULTS 
To determine if the Wnt pathway does in fact play a role in the pathogenesis of 
the Pax9-/- phenotype we chose to modulate the Wnt pathway in vivo by injecting the 
small molecule Dkk1 inhibitor (WAY-262611, Enzo Life Sciences) into pregnant Pax9+/- 
mice which had been mated with Pax9+/- males. Since Dkk1 is a potent Wnt inhibitor, 
expressed coordinately with Pax9 in dental mesenchyme, we expected WAY-262611 to 
be effective in increasing Wnt signaling activity and reversing any phenotypic symptoms 
of the Pax9-/- mouse embryos that were caused by down regulation of Wnt activity. We 
found that WAY-262611 could prevent the cleft palate phenotype of Pax9-/- mouse 
embryos (Figure 3-1), but not any of the other developmental malformations such as 
missing teeth, lack of pharyngeal pouch derivatives, or polydactyly. Thirteen out of a 
total of 15 Pax9-/- pups from 6 litters showed rescued palate fusion. However, the palatal 
fusion did not prevent postnatal death of the pups, indicating that other Pax9 target 
organs, such as parathyroid glands or thymus, may be more instrumental in perinatal 
lethality.  
Additionally, the WAY-262611 injections had no negative effects on the 
wellbeing of the mother or the health of the Pax9-/+ or Pax9+/+ littermates, both of which 
were followed for more than twelve weeks. The injection of vehicle (10% DMSO in 
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PBS) alone at E12.5, E13.5 and E14.5 did not rescue palate formation in Pax9-/- embryos 
(n=7).  
 
DISCUSSION 
In terms of preventing tooth agenesis, it is likely that Pax9 affects additional 
pathways besides just Wnt and therefore a therapeutic approach that targets several 
different pathways would probably be needed to be effective. Alternatively, a stronger 
boost in Wnt signaling or different Wnt pathway activator may be required. 
Wnt genes are known to regulate many developmental processes, including 
craniofacial development, but they are rarely mentioned as contributors to clefting 
disorders: One report describes a family with homozygous nonsense mutations in WNT3 
causing orofacial clefts as part of a Tetra-amelia syndrome (Niemann et al., 2004); and a 
few association studies also suggest that WNT3 may contribute to an increased risk for 
cleft lip/palate in humans (Menezes et al., 2010; Mostowska et al., 2012). In mice, 
investigators have shown that the cleft palate following retinoic acid administration 
during pregnancy is at least partly caused by inhibition of canonical Wnt signaling (Hu 
et al., 2013). Other investigators found that cleft lip with cleft palate caused by 
inactivation of Pbx genes also involves Wnt down-regulation; they succeeded in 
rescuing cleft lip but not cleft palate formation by ectopic ectodermal Wnt expression 
(Ferretti et al., 2011).  
The implications of our findings are the following: 1) The Wnt pathway seems to 
have a significant role in orofacial cleft development. 2) The paired domain transcription 
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factor Pax9 is involved in the regulation of Wnt pathway activity during the 
development of some craniofacial tissues. 3) Small molecule modulators of major 
signaling pathways have the potential to become effective drugs for the prevention of 
developmental malformations. 4) The critical targets of any developmentally active 
transcription factor are likely to differ from tissue to tissue requiring combination 
replacement therapy. 5) Temporally restricted administration of these agents may be 
tolerated without causing severe adverse effects. 
Finally, the possibility exists that WAY-262611 or Dkk1 have a wider spectrum 
of molecular activity besides affecting only Wnt signaling. Further investigation of this 
drug and the function of Dkk1is warranted to understand the exact mechanism that is 
driving their role in palatal growth, morphogenesis, and/or fusion. 
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CHAPTER IV 
IS THERE A LINK BETWEEN OVARIAN CANCER AND TOOTH AGENESIS?* 
 
SYNOPSIS 
An epidemiologic study from the year 2008 found a highly significant increase of 
congenital tooth agenesis in women with ovarian cancer suggesting that a common 
genetic etiology may predispose women to both conditions. The finding was reminiscent 
of a previously described family harboring an AXIN2 mutation which could be shown to 
segregate with both the tooth agenesis and the predisposition to colon cancer transmitted 
in this family. Since tooth agenesis as a marker for susceptibility to ovarian cancer 
would be of great relevance to both oncologists and women with inborn missing teeth, 
the relationship between the two disorders requires a thorough assessment. We examined 
DNA samples from the ovarian cancer patients who participated in the original study, to 
look for a possible genetic connection between their ovarian malignancies and tooth 
agenesis. MSX1, PAX9, AXIN2, EDA, WNT10A, BARX and BRCA1 genes were selected 
for sequence analysis as they may cause tooth agenesis, are expressed in the female 
reproductive system, and/or are involved in tumorigenesis in general or specifically in 
the ovary.
_________________
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Our study revealed evidence that one half of the dually affected patients had an 
independent causation of the two conditions, thus reducing the previously estimated 
ovarian cancer risk for women with congenital tooth agenesis quite significantly.
INTRODUCTION 
In 2008, Chalothorn et al. described an increased prevalence of congenitally 
missing teeth in women with epithelial ovarian cancer (Chalothorn et al., 2008).  Twenty 
percent of women with neoplastic ovarian disease reported one or two missing teeth, 
versus three percent in a cancer-free control sample. Surprisingly, ten ovarian cyst 
patients (unpublished) displayed an even greater prevalence of hypodontia: forty percent. 
These observations suggested that there may be common genetic factors affecting both 
tooth development and susceptibility to the formation of epithelial tumors or cysts of the 
ovary, similar to the sequence variant in the AXIN2 gene which causes both tooth 
agenesis and colorectal cancer (Lammi et al., 2004).  
Early detection of epithelial ovarian cancer is difficult and as a result, the 
mortality rate is unacceptably high. If a link were found between tooth agenesis and 
ovarian cancer, semi-annual screening could become the standard of care for women 
with tooth agenesis to increase the early detection rate (van Nagell et al., 2007). This 
would not only provide a new diagnostic tool but also open up new biological insight 
into epithelial ovarian cancer which, according to latest findings, may actually originate 
in the fallopian tube epithelium since gene expression patterns in these two tissues 
resemble each other closely (Kurman and Shih Ie, 2011). 
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The lifetime risk for neoplastic ovarian disease is only about a fifth of that for 
tooth agenesis, which occurs in approximately 3% to 9% of the population even when 3rd 
molars are excluded (Mattheeuws et al., 2004; Shapiro and Farrington, 1983). So far, 
sequence variants in WNT10A, MSX1, PAX9, AXIN2 and EDA pathway genes have been 
shown to cause about 50% of selective tooth agenesis in humans (Bergendal et al., 2011; 
Bohring et al., 2009; Lammi et al., 2004; Stockton et al., 2000; Tao et al., 2006; 
Vastardis et al., 1996). Several of these genes are also expressed in tumor cells of the 
female reproductive system, suggesting a possible mechanism for the relationship 
between ovarian disorders and hypodontia.  
The homeobox gene BARX2 is expressed in maxillary and mandibular arches 
(Jones et al., 1997 ) and in the developing tooth and is frequently dysregulated in 
epithelial ovarian cancer (Sellar et al., 2001; Sellar et al., 2002). BARX1, a related 
homebox gene, plays an important role in molar morphogenesis (Gould and Walter, 
2000).  
Overexpression of Msx1 inhibits ovarian carcinoma cell proliferation by 
inducing apoptosis through interaction with the tumor suppressor p53 (Park et al., 2005). 
MSX1 deficiency has been seen in human ovarian cancer cells (Park et al., 2001 ) and 
other malignancies (Peters and Balling, 1999). Sequence variants in MSX1 have been 
shown repeatedly to cause oligodontia of premolars, molars and incisors similar to 
PAX9, a paired box transcription factor which is thought to control mesenchymal Bmp4 
signaling during odontogenesis (Peters et al., 1998a). PAX9 expression was also found in 
five of six epithelial ovarian cancer cell lines examined (Muratovska et al., 2003).  
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AXIN2 is a member of the Wnt signaling pathway, which is highly conserved in 
evolution and controls many events during embryogenesis such as morphogenesis, 
proliferation, motility and cell fate. Individuals with AXIN2 sequence variants can have 
both tooth agenesis and a strong predisposition for developing colorectal cancer (Lammi 
et al., 2004; Mostowska et al., 2006). WNT10A is the most commonly altered gene in 
tooth agenesis (Bohring et al., 2009) with a large number of missing teeth in 
homozygotes, and a few missing teeth in about 50% of heterozygotes. Sequence variants 
in BRCA1 are the best-known causes of breast and ovarian cancer and, although the gene 
is also expressed in the developing tooth, it has never been implicated in tooth agenesis. 
The EDA gene is not associated with ovarian cancer or development, however, 
sequence variants of the EDA gene cause the syndrome X-linked Hypohidrotic 
Ectodermal Dysplasia (Li et al., 2008) and also non-syndromic tooth agenesis. Carrier 
females may present with one or two missing or malformed teeth. Therefore an EDA 
sequence variant found in any of the ovarian cancer samples would signify coincidental 
tooth agenesis. 
The primary goal of our study was to investigate if the five well-established tooth 
agenesis genes WNT10A, EDA, PAX9, MSX1, and AXIN2 as well as the BARX1, 2 and 
BRCA1 genes show any evidence of involvement in the tooth agenesis/ovarian cancer 
association by doing a thorough sequence analysis of these candidate genes in the 
original patient sample from the study by Chalothorn.  
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MATERIALS AND METHODS 
Subject recruitment  
The original protocol was IRB approved by the University of Kentucky. Fifty 
subjects with ovarian cancer and another ten with ovarian cystic disease, each with or 
without tooth agenesis, were recruited from the University of Kentucky Ovarian 
Screening Clinic. Inclusion criteria were peri- or post-menopausal, ages 45 or older and 
no obvious signs of a syndrome. Additional unrelated patients with tooth agenesis and 
no personal or family history of ovarian disease were recruited under a separate IRB 
approval from Texas A&M University Baylor College of Dentistry. All participants 
were Caucasians except one who was of Japanese ancestry. 
The final patient cohorts consisted of four groups: 1) 10 patients with agenesis of 
1 to 2 teeth and ovarian cancer, 2) 40 patients with only ovarian cancer, 3) 35 patients 
with agenesis of 1-8 teeth without ovarian disorders, and 4) the 10 patients with ovarian 
cysts of whom 4 had mild tooth agenesis.  
The wild-type sequence and allele frequencies of common variants in control 
populations were obtained from the NCBI SNP database and the NHLBI Exome 
sequencing project (ESP).  Wild-type reference sequences obtained from NCBI are as 
follows: MSX1 (NM_002448.3), PAX9 (NM_006194.3), AXIN2 (NM_004655.3), EDA 
(NM_001399.4), WNT10A (NM_025216.2), BARX1 (NM_021570.3), BARX2 
(NM_003658.4) and BRCA1 (NM_007294.3). 
Informed consent was obtained and a thorough patient history and dental exam 
was performed. If a patient was unsure of history, the patient’s dentist was consulted to 
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confirm etiology of any missing teeth. DNA samples were obtained using BuccalAmp 
swabs and sent to Texas A&M University Baylor College of Dentistry for analysis. 
 
DNA extraction from buccal swabs  
Since buccal swabs may not have yielded sufficient material for the analysis of 
eight to ten genes, the samples were amplified by Whole Genome Amplification (WGA) 
with the GenomiPhi WGA system (GE Healthcare). Successful genome amplification 
was verified by gel electrophoresis of amplified samples together with a quantitation 
marker. 
 
Polymerase chain reaction and sequencing of products  
The exons of each gene were PCR amplified with GoTaq reagents (Promega) 
using a 96-well plate format for the 95 samples and one negative control. Several of the 
amplicons were very GC-rich and required PCR optimization and the use of 5% DMSO. 
Quality and quantity of PCR products was confirmed by gel-electrophoresis, followed 
by treatment with ExoSapIt (Affymetrix) and then addition of specifically designed 
sequencing primers. Automated dideoxy chain terminator sequencing was done by 
Seqwright, TX and GenScript, NJ. 
 
Analysis of sequencing results  
All sequences were visually inspected for heterozygous base changes and 
compared to the corresponding wild-type sequences previously mentioned using the 
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NCBI BLAST program. Once a nucleotide change was found, the SNP (single 
nucleotide polymorphism) database was consulted to determine if the SNP is a common 
polymorphism. For common SNPs, the allele frequencies were compared 1) between the 
different experimental groups and 2) between experimental groups and Caucasian 
population controls reported in NCBI and NHLBI databases. For MSX1 polymorphisms, 
the Caucasian control allele frequencies from a study by Jezewski et al. (supplement) 
were also employed (Jezewski et al., 2003). Chi-square statistics was used for the 
determination of statistical significance of allele frequency differences.  
 
RESULTS 
Sequence analysis of the EDA, WNT10A and BRCA1 genes yielded several 
interpretable results (Table 4-1): 
1) One of the ten patients with combined ovarian cancer/tooth agenesis was a 
carrier of the known p.Arg69Leu sequence variant in EDA (rs132630309), explaining 
the tooth agenesis, and she also had a frameshift sequence variant in BRCA1, 
p.Gln1096_Ser1097=fs (rs80357686), most probably responsible for the ovarian cancer. 
2) Another tooth agenesis/ovarian cancer patient had the BRCA1 frameshift 
sequence variant, p.Lys679Ter (rs80357082), which was also present in two other 
ovarian cancer patients without tooth agenesis, indicating that this patient’s ovarian 
cancer and her tooth agenesis have different roots and also that the investigated 
population shared common ancestors since the frequency of this sequence variant seems 
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to be quite high, but no population allele frequencies are available (presumably due to 
gene patent issues). 
3) Three of the remaining eight tooth agenesis/ovarian cancer patients had the 
WNT10A p.Phe228Ile sequence variant (rs121908120), which in heterozygous form is 
probably the most common sequence variant encountered in mild tooth agenesis while 
causing severe tooth agenesis when homozygously inherited. There were also three 
patients with this sequence variant in the “ovarian cancer only” group, however about 
50% of people with this sequence variant normally do not present with tooth agenesis. 
These results taken together suggest that at least half of the samples from the 
combined ovarian cancer/tooth agenesis patients identified in the epidemiological study 
by Chalothorn et al. show evidence for independent causation of the two conditions. In 
the ten ovarian cyst patients we found sequence variants neither in BRCA1 nor in the 
tooth agenesis genes WNT10A or EDA. 
Sequence analysis results from the other investigated genes are presented in 
Tables 4-2 and 4-3 and are briefly presented below. These results were calculated for the 
whole group, including ovarian cancer and ovarian cyst groups. 
In BARX1, the missense sequence variant Ala48Thr was detected in 17 samples, 
but no significant allele frequency differences between the groups were found. The other 
five polymorphisms in this gene were also insignificant. 
In BARX2, we found four heterozygous p.Ser64Pro sequence variants; three of 
them in individuals with tooth agenesis, with and without ovarian cancer. p.Ser64Pro is 
fairly conserved among species suggesting its importance in protein function; however 
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since the control allele frequency reported in the SNP database is similar to the one 
found in this study, it may not play a role in tooth agenesis. On the other hand, we do not 
know if the control population used for SNP data was screened for missing teeth. The 
synonymous p.Pro203= polymorphism in exon 2 occurred in the ovarian cancer cohort 
in 50% of those with tooth agenesis versus 33% without tooth agenesis; however, the 
difference was not statistically significant. The remaining polymorphisms found for 
BARX2 did not demonstrate allele patterns consistent with an association with a disease 
phenotype.  
A substantial number of polymorphisms were found in the MSX1 gene including 
p.Ala40Gly (formerly p.Ala34Gly). The minor allele frequency of this polymorphism 
was significantly higher in all groups with tooth agenesis (regardless of ovarian disease 
status) compared to the NHLBI ESP Caucasian control group (n> 2,000). However using 
the allele frequency values for 154 Caucasian controls which were reported by Jezewsky 
et al. in their study about MSX1 sequence variants in cleft lip/palate patients (Jezewski et 
al., 2003), the differences were not statistically significant. The allele frequencies of the 
MSX1 polymorphisms c.*6C>T (rs8670) and c.-18G>A (rs186861426) were also 
significantly higher in most groups with tooth agenesis using the NHLBI ESP (Table 4-
3), but not with the Jezewski control frequencies; we also noticed that these SNPs appear 
to be syntenic with p.Ala40Gly.  
In AXIN2 we found the missense sequence variant p.Ser762Asn in a single 
ovarian cancer patient without tooth agenesis. This sequence variant may thus contribute 
to cancer susceptibility but not to tooth agenesis. We also found the previously reported 
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c.1994_1995insG sequence variant in one patient with combined ovarian cysts and tooth 
agenesis; however, we suspect that it is a PCR artifact since its appearance was 
dependent on PCR conditions and it occurs after a run of seven G nucleotides.   
Sequencing of PAX9 revealed five known and one new polymorphism (Table 4-
2). One of these, a C to T transition adjacent to the p.Ala240Pro polymorphism, lead to a 
synonymous histidine codon which was significantly more frequent in samples from 
tooth agenesis patients (Table 4-3). 
 
DISCUSSION 
A genetic connection between development and cancer is intuitively 
understandable in that both processes are characterized by rapid cell growth which often 
involves the same signaling pathways. However it is less intuitively understandable that 
a developmental deficit like tooth agenesis should be associated with the uncontrolled 
expansion of cell growth found in cancer. The finding that a nonsense sequence variant 
in AXIN2, which should lead to increased WNT signaling, can cause both severe tooth 
agenesis and a predisposition for colon cancer in humans (Lammi et al., 2004) is 
therefore somewhat surprising because increased WNT signaling leads to supernumerary 
teeth in experimental animal models (Jarvinen et al., 2006) and Axin2 promotes 
oncogenicity in colon cancer by the upregulation of Snail1 (Wu et al., 2012). Thus, only 
a gain-of function sequence variant, not a nonsense sequence variant, in Axin2 would be 
compatible with its double role as suppressor of tooth development and promoter of 
colon cancer. The double role is easier to fathom in the case of sequence variants in 
 44  
 
MSX1, a protein that is able to interact with both DNA and other proteins and can act as 
a transcriptional suppressor or as an activator depending on cellular context. 
Since a causal linkage between tooth agenesis and ovarian cancer would have 
major ramifications for the large number of women with minor tooth agenesis, the issue 
requires quite urgent clarification. Therefore, we undertook this investigation and 
approached the question of common genetic factors in tooth agenesis and ovarian cancer 
by screening known tooth agenesis causing genes for sequence variants as suggested in 
the original study by Chalothorn and also added the BRCA1 gene and the newly 
attributed tooth agenesis gene WNT10A.  
We did not find a single candidate gene or sequence variant that could explain 
the increased co-occurrence of tooth agenesis with ovarian cancer or ovarian cysts with 
the exception of the controversial c.1994_1995insG sequence variant in Axin2. But we 
did find BRCA1 sequence variants in two of the ten cases of ovarian cancer/tooth 
agenesis patients, explaining the ovarian cancer. Additionally, one of these two also had 
an EDA sequence variant, clearly demonstrating separate origins of ovarian cancer and 
tooth agenesis. Furthermore, we found well known tooth agenesis-causing WNT10A 
sequence variants in three additional members of the ovarian cancer/tooth agenesis 
group arguing for independent causation of the tooth agenesis in these patients. Our 
findings do not prove that the two conditions arose independently from each other but 
they make it seem quite likely for at least half of the cases. 
The observation by Chalothorn et al. that their 10 ovarian cyst patients had an 
even higher prevalence of hypodontia than the ovarian cancer cohort reinforces this 
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notion since so far no genetic link has been detected between epithelial ovarian cancer 
and ovarian cysts making it unlikely that a single gene may be responsible for all 3 
disorders. 
Additional evidence for independent causation comes from a recent study which 
did find increased rates of (self-reported) cancer in patients with tooth agenesis (Kuchler 
et al., 2013). However, ovarian cancer, in contrast to prostate, breast, and nervous 
system malignancies, was not among the significant results. We also have been enrolling 
a few hundred subjects in our own “Missing Tooth Study” over the past 10 years and 
have not noted any case with ovarian cancer or cysts in her/his family’s medical history; 
however, the reason for this could be the higher prevalence of tooth agenesis and 
incomplete recall of family health issues.  
On the other hand, we know that the investigated genes represent only a minority 
of all the possible candidates that may be involved in hypodontia and it would certainly 
be worthwhile to investigate additional genes which are commonly associated with 
ovarian cancer such as BRCA2, BRCA-interacting protein, ErbB2 and p53, for example, 
which are also quite strongly expressed in the tooth bud of developing mouse embryos 
(Diez-Roux et al., 2011).  
In conclusion we propose that a larger epidemiological study should be 
conducted to confirm any link between ovarian cancer and tooth agenesis and challenge 
the currently held notion of a predisposition of developing cancer in tooth agenesis 
patients. Ideally, a large family with both ovarian cancer and tooth agenesis may be 
recruited for linkage analysis. 
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CHAPTER V 
THE WNT10A GENE IN ECTODERMAL DYSPLASIAS AND SELECTIVE TOOTH 
AGENESIS* 
 
SYNOPSIS 
 Mutations in the WNT10A gene were first detected in the rare syndrome odonto-
onycho-dermal dysplasia (OODD, OMIM257980) but have now also been found to 
cause about 35–50% of selective tooth agenesis (STHAG4, OMIM150400), a common 
disorder that mostly affects the permanent dentition. In our random sample of tooth 
agenesis patients, 40% had at least one mutation in the WNT10A gene. 
TheWNT10A Phe228Ile variant alone reached an allele frequency of 0.21 in the tooth 
agenesis cohort, about 10 times higher than the allele frequency reported in large SNP 
databases for Caucasian populations. Patients with bi-allelic WNT10A mutations have 
severe tooth agenesis while heterozygous individuals are either unaffected or have a 
mild phenotype. Mutations in the coding areas of the WNT10B gene, which is co-
expressed with WNT10A during odontogenesis, and the WNT6 gene which is located at 
the same chromosomal locus as WNT10A in humans, do not contribute to the tooth 
agenesis phenotype.
__________________
 
 
 48  
 
INTRODUCTION 
Adaimy et al. (2007) performed autozygosity mapping in three consanguineous 
Lebanese families with the rare Odonto-Onycho-Dermal-Dysplasia syndrome (OODD,
MIM 257980) which had been previously characterized phenotypically in the same 
population (Fadhil et al., 1983). They found that all affected family members were 
homozygous for the same nonsense mutation in the WNT10A gene leading to the 
phenotypic features of severe hypodontia, onychodysplasia, smooth tongue as well as 
palmar and plantar hyperhidrosis and hyperkeratosis. The phenotype of heterozygous 
family members was not recorded. Two years later Bohring et al. (2009) reported that 
WNT10A mutations are not restricted to the rare OODD syndrome but also found in 
other Ectodermal Dysplasia entities like the Schöpf-Schulz-Passarge syndrome (MIM 
224750) which additionally features eyelid cysts and predisposition to adnexal skin 
tumors. Bohring et al. also described a high prevalence of apparently non-syndromic 
tooth agenesis among their homozygous patients as well as mild, predominantly dental 
symptoms in about half of the heterozygous family members. Three further reports about 
the high prevalence of WNT10A mutations in Ectodermal Dysplasia syndromes and in 
non-syndromic tooth agenesis followed in 2011 (Cluzeau et al.), in 2012 (van den 
Boogaard et al.), and in 2013 (Plaisancie et al.). 
The expression of Wnt10a along with Wnt10b, Shh, Bmps2 and 4 and other 
developmentally active gene products during mouse odontogenesis had been 
investigated as early as 1998 (Dassule and McMahon). They detected Wnt10a at around 
mouse embryonic day 12 (E12) by in situ hybridization in the inner epithelial/ enamel 
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knot area of the tooth bud, where it was co-expressed with Wnt10b. Since Wnt10b 
expression was recognizable a little earlier and more prominently than Wnt10a 
expression, further investigations in this study focused on the Wnt10b molecule. At later 
stages of tooth development (mouse E14 to E18), Wnt10a can also be found in the 
mesenchymal preodontoblast layer where it contributes to or initiates odontoblast 
differentiation, possibly through the up-regulation of dentin sialophosphoprotein (Dspp) 
expression (Yamashiro et al., 2007).  
WNT10A, which is located adjacent to WNT6 at 2q35 in humans, is also active 
during the development of hair follicles and limbs, and in hematopoiesis. In adult tissues 
it is expressed in lymph nodes, blood, adrenal gland, prostate, testis, ovary, retina, brain, 
lung and kidney; and may also play a role in several neoplastic disorders, notably 
ameloblastomas, keratocystic odontogenic tumors, lymphomas and leukemias but is also 
found up-regulated in several cancers. Functional studies showed that Wnt10a activates 
the canonical Wnt pathway and regulates mesenchymal cell fate in that it inhibits 
adipogenesis and stimulates osteoblastogenesis (Cawthorn et al., 2012). 
The general role of canonical Wnt signaling during tooth development has been 
explored in more detail by stabilization of β-catenin or depletion of Apc, a positive and a 
negative regulator of canonical Wnt signaling respectively. Both procedures 
constitutively activate Wnt signaling in tooth bud epithelium leading to the formation of 
many accessory tooth buds sprouting from the original tooth anlage. The resulting 
supernumerary teeth are often small but otherwise completely normal (Jarvinen et al., 
2006; Wang et al., 2009a). Interestingly, the expression of Pax9 and Msx1, two normally 
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essential transcription factors in tooth bud mesenchyme, are not required for the 
formation of these supernumerary teeth. Furthermore, the inactivation of the Wnt 
secretion facilitator Wntless (Wls) was recently shown to prevent intraepithelial Wnt 
signaling leading to tooth developmental arrest (Zhu et al., 2013). 
When we sequenced the WNT10A gene in the random collection of tooth 
agenesis patients who participate in our “missing tooth” study, we also found a large 
number of WNT10A mutations in our samples confirming the importance of WNT10A 
in tooth development. 
 
MATERIALS AND METHODS 
Patient recruitment 
 Tooth agenesis study participants were recruited via website and through 
collaboration with Drs. Alexandre Vieira (University of Pittsburgh) and Ophir Klein 
(University of California at San Francisco), following IRB approved protocols. People of 
all ages with any number of missing teeth except third molars were included, and only 
patients with overt ectodermal dysplasia symptoms were excluded. The final cohort 
consisted of 90 unrelated samples; half of them were from Caucasian Americans and the 
other half from patients from Turkey which are considered to be mostly of 
Mediterranean- European ancestry. Cheek swab or saliva samples were collected for the 
isolation of genomic DNA. The wild type sequence and allele frequencies of common 
variants in control populations were obtained from the NCBI SNP data bases as well as 
the NHLBI Exome sequencing project (ESP).  
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DNA extraction from buccal swabs 
 DNA extraction was performed with the Puregene Buccal Cell Kit (Qiagen). 
Since buccal swabs do not yield sufficient material for the analysis of multiple genes, the 
samples were amplified by Whole Genome Amplification (WGA) with the REPLI-g 
WGA system (Qiagen) Successful genome amplification was verified by gel 
electrophoresis of amplified samples together with a quantitation marker. DNA samples 
received from our collaborators were also amplified by WGA. 
 
Polymerase chain reaction and sequencing of products 
Exons of the WNT10a, WNT10b and WNT6 genes were PCR amplified with 
GoTaq reagents (Promega) using a 96-well plate format for the 90 samples and the 
controls. Quality and quantity of PCR products was confirmed by gel-electrophoresis, 
followed by treatment with ExoSapIt (USB) and addition of the sequencing primers. 
Automated dideoxy chain terminator sequencing was done by GenScript, Piscataway, 
NJ. 
 
Analysis of sequencing results 
All sequences were visually inspected for heterozygous base changes and 
compared to the corresponding wild type sequences using the ‘BLAST’ program. Once a 
nucleotide change was found, the SNP (single nucleotide polymorphism) data base was 
consulted to determine if the SNP is a common polymorphism. For appropriate SNPs, 
the allele frequencies were compared between the experimental groups consisting of 
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Caucasian and Turkish samples; and between the experimental and the Caucasian 
population control groups reported in NCBI and NHLBI data bases.  
 
RESULTS 
Wnt10A but neither WNT6 nor WNT10B contribute to tooth agenesis 
About forty percent of our random group of tooth agenesis patients had at least 
one missense, nonsense or frameshift mutation in the WNT10A gene. The different 
mutations encountered in our patient samples are shown in Figure 5-1. Most common 
was the mono- or bi-allelic Phe228Ile mutation with a prevalence of about 31 percent 
and an allele frequency of 0.21 compared to an allele frequency of about 0.02 in large 
Caucasian control populations and only 0.007 in African American controls (Table 5-1). 
The allele frequency of Phe228Ile was also calculated separately for our Caucasian 
(0.216) and Turkish participants (0.20) to exclude any influence that ethnic background 
differences could have had on the allele frequency.  
Since Phe228Ile is so much more common in Caucasian tooth agenesis patients, 
it either is the causative factor or is closely linked to the causative mutation. Since 
WNT10A is located only a few kb telomeric of WNT6 on chromosome 2q35 we included 
the latter in our analysis but did not find any mutations or polymorphisms that were 
syntenic with the nucleotide change leading to WNT10A Phe228Ile. The common 
WNT6 variant Pro155Arg occurred in our tooth agenesis population at a frequency 
similar to normal control populations and only 1 of the 10 patients who had the WNT6 
Pro155Arg variant also had WNT10A Phe228Ile. 
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Since the WNT10A and WNT10B proteins are co-expressed in the inner dental 
epithelium of developing teeth and share 62 percent identity, it was conceivable that 
WNT10B mutations may also cause missing teeth. But sequencing of the whole coding 
area of the WNT10B gene did not reveal any nucleotide changes that could possibly be 
implicated in the tooth agenesis phenotype.  
 
Phenotypes associated with WNT10A mutations 
We did not receive any reports about missing primary teeth although some 
patients remembered having relatively small deciduous teeth. The number of missing 
teeth in the permanent dentition depended strongly on whether the affected individual 
was heterozygous or homozygous/ compound heterozygous for WNT10A mutations. 
Heterozygous patients were missing up to 6 permanent teeth while homozygous patients 
were generally missing from 6 to 26, most often 16 teeth.  
While all patients with bi-allelic mutations had oligodontia, many heterozygous 
relatives of study participants were not affected suggesting incomplete penetrance 
(Figure 5-2). Syndromic ectodermal dysplasia manifestations were not encountered in 
our study population because they constituted exclusion criteria for participation in the 
study. One study participant however had a history of benign skin tumors, possibly 
bearing some resemblance to the Schöpf-Schulz-Passarge syndrome and another one 
reported mild heat intolerance. 
The tooth agenesis pattern in heterozygous patients parallels that of common 
mild tooth agenesis with a predominant absence of lower second premolars and upper 
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lateral incisors; but mandibular incisors are also frequently absent, occasionally even a 
canine or a first premolar. The pattern is similar to EDA pathway associated selective 
tooth agenesis in that the anterior teeth are more often affected (Mues et al., 2010; Mues 
et al., 2009; Tarpey et al., 2007). Patients with homozygous WNT10a mutations have 
also posterior tooth agenesis similar to syndromic EDA pathway mutation phenotypes 
(Lexner et al., 2007). 
 
DISCUSSION 
Traditionally we distinguished between syndromic and non-syndromic tooth 
agenesis. Syndromic tooth agenesis was most often encountered as part of an Ectodermal 
Dysplasia phenotype while non-syndromic tooth agenesis, also called isolated or 
selective tooth agenesis/hypodontia (STHAG1-6 and X1 in OMIM), should only affect 
the dentition without any systemic manifestations. Inherent in the syndromic versus non-
syndromic classification was the assumption that the two disorders had fundamentally 
different genetic causations. 
However, the more we learn about the pathogenesis of tooth agenesis the more 
we realize that there is an extensive overlap between the genetic basis of syndromic and 
non-syndromic forms of tooth agenesis (Nieminen, 2009) and the phenotypic distinction 
may not have been helpful for the search of additional tooth agenesis genes. From a 
genetic point of view, non-syndromic and syndromic tooth agenesis are often caused by 
the same genes, but the development of some teeth seems to be more sensitive to gene 
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dosage and thus are the first organs to be affected, while other ectodermal appendices 
may still form normally (Mues et al., 2010). 
The distinction between syndromic and non-syndromic tooth agenesis may also 
be problematic with respect to the new, biologically based diagnostic and therapeutic 
approaches for which dental professionals who are traditionally the only health care 
providers for non-syndromic tooth agenesis patients, may still be little prepared. 
Classification of the STHAGs as ectodermal dysplasia entities may therefore be 
desirable from a clinical point of view. 
The high prevalence of WNT10A mutations is truly astounding, especially since 
this gene is hardly ever mentioned in the extensive literature about the molecular 
genetics of tooth development. Even more surprising is the large number of Caucasian 
tooth agenesis patients with one particular mutation, WNT10A Phe228Ile. Pathogenic 
mutations are usually lost from the gene pool of a population unless they have some kind 
of survival advantage like for example heterozygous mutations in the hemoglobin genes 
which are of benefit in areas with high malaria incidence. The survival advantage is 
often lost in individuals with homozygous mutations like in sickle cell disease, but since 
homozygously affected individuals are quite rare, the mutation has an overall positive 
effect on population growth (Fleming et al., 1979). It will certainly be interesting to find 
a cause for the high prevalence of WNT10A Phe228Ile mutations. 
Interesting is also that the tooth agenesis pattern of patients with WNT10A 
mutations resembles that of EDA pathway associated hypodontia. Both WNT and EDA 
pathways are known to operate predominantly in the epithelial layer of the developing 
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tooth and repeated interactions between the two pathways have been observed during 
ectodermal appendage formation and in vitro (Durmowicz et al., 2002; Laurikkala et al., 
2001; Zhang et al., 2009a). It is therefore possible that the new, biological replacement 
therapies for EDA pathway mutation associated disorders may also be of value in the 
much more common WNT10A disorder. It would certainly be worth testing this 
possibility because EDA replacement therapies have shown great efficacy in 
ameliorating disease symptoms in animals and are currently tested in humans, while the 
generation of WNT10A specific therapeutics would be quite complicated not only from 
a chemical engineering point of view but also because of the lack of a one to one 
correspondence of ligands and receptors in the WNT pathway, potentially leading to 
severe adverse effects, and even more importantly, a lack of a Wnt10a-deficient, 
diphyodont animal model for the testing of these therapeutics. 
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CHAPTER VI 
CONCLUSION 
 
In this project I investigated both the basic science and clinical aspects of the 
molecular genetics of tooth agenesis in order to:  
A) Characterize those target genes of the transcription factor Pax9 which mediate 
the tooth developmental arrest observed with Pax9 deficiency. These target genes have 
not only the potential to serve as therapeutics for the rescue of the tooth developmental 
arrest but may also be tooth agenesis causing genes themselves deserving to be screened 
for mutations in tooth agenesis patients.  
B) Identify the particular mutations in known or suspected tooth agenesis genes 
that are responsible for the tooth agenesis in each individual of a large group of patients 
with inborn missing teeth. An accurate molecular diagnosis is required before any 
molecular therapeutics can be used and the majority of the as yet unknown tooth 
agenesis genes should be discovered.  
The initial project in which I studied the downstream effects of Pax9 revealed 
that the regulatory mechanisms surrounding tooth agenesis were not as straightforward 
as previously thought. The most intriguing aspect of this study is that the gene that was 
presumed to be the central downstream effector of Pax9 on tooth formation, Bmp4, had 
mRNA levels that were relatively unchanged in our Pax9-deficient model during early 
tooth formation. This coupled with the fact that many other signaling pathways were 
much more heavily affected indicates that tooth agenesis cannot be easily attributed to 
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the loss of a single gene or gene product downstream of the causative gene and may 
therefore require treatment with multiple replacement factors if the mutated gene product 
itself is not suitable for replacement.  
The signaling pathways that appear to be markedly affected by Pax9 deficiency, 
Wnt, Fgf and Shh, were previously thought to be relatively minor targets of Pax9 or the 
result of diminished Bmp4 activity. The latter seems unlikely in light of our finding of 
barely changed Bmp4 expression.  
The impact of Pax9 on Wnt pathway regulators is of special interest because 
recent clinical studies indicate that mutations in one Wnt pathway member, the 
WNT10A gene, may be responsible for approximately 40% of all congenital human 
tooth agenesis. In concord with this clinical finding, many basic research studies have 
also detected the importance of the Wnt pathway which is gradually being revealed to be 
the master regulator of tooth formation, much like it is a major player in limb formation. 
Constitutively activated Wnt signaling has even been shown to overcome the tooth 
developmental arrest in Pax9 deficient murine tooth buds (O'Connell et al., 2012).  
To test the effects of a temporary and physiologically more tolerable increase in 
Wnt signaling in our Pax9-deficient mouse model we used a small molecule Wnt agonist 
(an antagonist of the Wnt inhibitor Dkk1 which was upregulated in Pax9-/- mice at 
E14.5). Injection of small amounts of this molecule into the maternal tail vein at discreet 
times during embryonic development led to the surprising finding that we could rescue 
the cleft palate phenotype of the Pax-/- embryos but the tooth phenotype was unchanged. 
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Nevertheless, another fortunate finding was that there were no apparent deleterious 
effects of using this molecule on normal and healthy wild-type embryos or the mother.  
Originally it was assumed that the cleft palate was to blame for the postnatal 
death of Pax9-deficient pups. However, pups with rescued palate still died at birth, with 
the cause now most likely being the lack of development of other missing pharyngeal 
pouch derivatives. Hind limb polydactyly was also unchanged, presumably because the 
drug was given after the start of limb and digit formation. It would be interesting to see 
if this polydactyly would be corrected by earlier application of the drug. Most likely, 
however, at this earlier stage of development, around E10, the treatment would produce 
more undesirable side effects. Since we could rescue the cleft palate but no other 
phenotype manifestations of Pax9 deficiency, we suggest that combination therapy may 
be needed to totally restore Pax9-deficient mice, for example adding recombinant Fgf3, 
4 and/or an Shh agonist like the Smoothened Agonist, SAG.  
We also tested the effect of injecting the Bmp4 agonist isoliquiritigenin (not 
published). This molecule was shown to act as a Bmp4 agonist in cell culture and in 
zebrafish; however, it had not yet been tested in mammals. Our results showed that there 
was no effect of this treatment suggesting that either this molecule does not perform well 
in mammals or that Bmp4 deficiency is not a major cause of the Pax9-deficient 
phenotype. Based on our microarray and RT-qPCR results it is most likely the latter. 
The other aspect of this dissertation focuses on clinical approaches to diagnose 
the molecular genetic causes of tooth agenesis in individual patients. In order to find new 
tooth agenesis genes we screened several of our newly discovered Pax9 downstream 
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target genes (Fgf3, Fgf4, Tcfap2b, Sostdc1, Lef1 and others) for mutations in 90 
independent DNA samples from patients with tooth agenesis. None of the chosen genes 
showed mutations in our tooth agenesis samples except for one rare polymorphism in 
Lef1 which may have contributed to the tooth agenesis phenotype of the donor of that 
sample. 
Our study also investigated the alleged association of ovarian cancer with tooth 
agenesis and showed that there was essentially no increased risk for women to acquire 
ovarian cancer if they had missing teeth because we found through candidate gene 
sequence analysis that the tooth agenesis and the ovarian cancer most probably arose 
independently from each other. The importance of our study is obvious since tooth 
agenesis is the most common developmental abnormality in humans and this high 
prevalence would lead to unnecessary anxiety in many women who, in reality, are not at 
an increased risk at all of developing a malignant neoplasm. Studies such as this suggest 
the need to further investigate issues where clinical associations suggest causality when 
in fact there is only a correlation. 
We also showed through diagnostic gene sequencing in 90 tooth agenesis 
samples that all known Wnt mutations that affect tooth formation reside within the 
WNT10A gene and not within other Wnt genes such as WNT6 which is located adjacent 
to WNT10a on chromosome 2 or Wnt10b which is co-expressed with WNT10A during 
tooth development. Also of note is that a single mutation, Phe228Ile, is astonishingly 
common in Caucasian populations and yet there does not seem to be an advantage to this 
mutation. Usually harmful mutations are lost from the gene pool unless they have 
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heterozygote advantage such as mutations in hemoglobin in individuals with sickle cell 
anemia who gain resistance to malaria. It would seem that the great unsolved question is 
what kind of heterozygote advantage a reduced Wnt10a activity could have. 
Our overall conclusion is that it should be possible to rescue genetically caused 
developmental disorders by substitution of the crucial gene products at the correct 
developmental time interval. The substitution therapy may consist of recombinant 
proteins or small molecule genetic pathway regulators and may require only one factor 
in the case that the dysfunctional gene product can be replaced directly, or it may require 
the replacement of several factors if downstream targets of the dysfunctional gene 
product have to be used. In any case the genetic cause of the developmental disorder has 
to be diagnosed before the appropriate replacement therapy can be determined. 
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APPENDIX A 
FIGURES 
Figure 2-1. RT-qPCR data versus microarray data for E14.5. 
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Figure 2-1 Continued. 
FGF3, SHH, and TFAP2B all showed a >9.5-fold change (E14.5). Most microarray gene 
expression values align with their RT-qPCR counterparts except for DAAM1 and  
ODAM. DAAM1 showed overexpression in the array while RT-qPCR showed very 
slight under-expression. ODAM’s relative fold change was no different from wild-type 
values when performing RT-qPCR. 
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Figure 2-2: Relative gene expression pattern in Pax9
-/-
 tooth organs at E13.5 and 
E14.5 
 
Pax9-deficient gene expression levels in E13.5 and E14.5 relative to wild-type 
expression. Note that Bmp4 levels are only slightly reduced in the Pax9-deficient tooth 
organs while Fgf3 and Shh are greatly reduced. Dkk1, a potent Wnt antagonist, has an 
increased expression level which suggests reduced Wnt activity. 
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Figure 3-1. Rescue of cleft palate in Pax9
-/-
 E18.5 embryos. 
 
a.) E18.5 Pax9-/- untreated embryo. b.) E18.5 wild-type (Pax9+/+) embryo.  Note normal 
development of palate and tooth organs. c.) E18.5 Pax9-/- treated with 12.5 mg/kg WAY-
262611 at E12.5, E13.5, and E14.5. Arrows indicate dental lamina arrested at early bud 
stage (a and c) and normal tooth organs (b); *** indicates secondary cleft palate; white 
arrowhead indicates fused palate. 
 
 
 75  
 
Figure 5-1. WNT10A mutations found in our tooth agenesis patient cohort.
 
e4=exon4 of WNT10A, fs=frame shift, F=Phenylalanine, I=Isoleucine, W=Tryptophan, 
N=Asparagine, R=Arginine, V=Valine, M=Methionine, H=Histidine, C=Cysteine, 
G=Glycine, S=Serine. 
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Figure 5-2. Incomplete penetrance and phenotypic variability of WNT10A 
 
Two pedigrees showing incomplete penetrance and variability of the phenotype 
depending on the number of WNT10A alleles affected. The fifth generation of the 
pedigree on the left is still too young for phenotype evaluation. An additional feature in 
this family is that the husband of the homozygous index patient (arrow) also carries the 
F228I variant, a 1 in 50 chance. The pedigree on the right also shows that two different 
tooth agenesis genes may contribute to the phenotypes, because the daughter has several 
missing teeth but no F228I mutation while her two homozygous brothers have severe 
tooth agenesis. F=Phenylalanine, I=Isoleucine 
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APPENDIX B 
TABLES 
Table 2-1. DEGs with a >1.5-fold change between wild-type and Pax9/Osr2 knock-
in mice at E14.5 (microarray data). 
Function 
Fold Change 
1.5-2.0 2.0-3.0 3.0+ 
Transcriptional 
Regulator 
FOXF1A, TRP63, 
EGR2, MSX1 
OSR2, TFAP2C PAX9, EGR3 
Other DKK1, LEF1 
DAAM1, GSTM6, 
G2E3, HAS3, 
KRT17, DKK4 
ADI1, ODAM, 
SHH 
Unknown DLX1AS, VWA2 VEPH1 C1QTNF3 
Red indicates a down-regulated gene and blue indicates an up-regulated gene.  All genes 
show a positive signal in the E14.5 tooth bud according to the Eurexpress database. 
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Table 4-1. Sequence variants found in ovarian cancer patients with or without tooth 
agenesis. 
 
Pt# 
BRCA1 
(NM_007294.3) 
EDA 
(NM_001399.4) 
WNT10A 
(NM_025216.2) 
AXIN2 
(NM_004655.3) 
TOOTH AGENESIS PHENOTYPE 
2   p.Phe228Ile   
3    p.Ser762Asn  
5 p.Lys679stop     
7 p.Lys894fs     
10 p.Lys527fs     
13 p.Lys894fs     
14     1 upper lateral incisors 
16   p.Phe228Ile  1 upper 2nd premolar 
19 p.Met1652Ile     
20   p.Phe228Ile   
27     1 lower 2nd premolar 
29     2 upper lateral incisors 
30   p.Phe228Ile  2 upper lateral incisors 
32   p.Phe228Ile  1 upper 2nd premolar 
33 p.Gln1096fs p.R69L   upper lateral peg 
34   p.Phe228Ile   
35 p.Lys894fs    2 upper lateral incisors 
36     1 upper 2nd molar 
43     1 upper lateral incisor 
56    c.1994_1995insG 1 upper lateral incisor, 1 upper 1st premolar 
Ovarian Cancer patients with/without tooth agenesis who were found to have sequence 
variants in the breast/ovarian cancer gene BRCA1 and the tooth agenesis genes EDA and 
WNT10A. Bold entries represent patients with combined ovarian cancer/tooth agenesis; 
the others have ovarian cancer without tooth agenesis. Patient numbers 1-50 are ovarian 
cancer patients; #56 is an ovarian cyst patient. Phenotypes were previously reported by 
Chalothorn. 
  
 79  
 
Table 4-2. All sequence variants and their allele frequencies in selected study 
groups. 
SEQUENCE VARIANT ALLELE FREQUENCY (MINOR ALLELE) 
REMARKS 
Gene rs# Location 
Total 
(n=95) 
OV±TA 
(n=60) 
TA±OV  
(n=49) 
OV+TA 
(n=14) 
Control 
PAX9 
(NM_006194.3) 
rs12881240 p.His239= 0.30’ 0.24 0.31’ 0.18 0.20 Significant NHLBI 
rs4904210 p.Ala240Pro 0.31 0.34 0.26 0.29 0.36  
rs61734510 p.K172= 0.011 0.008 0.01  0.008  
rs17104965 c.*259C>T 0.032 0.033 0.031 0.036 0.02  
rs17766200 c.*429T>C 0.126 0.075 0.163 0.036 0.093  
 c.*209G>T 0.005  0.01    
MSX1 
(NM_002448.3) 
 c.-243G>A 0.01 0.008 0.01   Promoter region 
rs186861426 c.-18G>A 0.12’’ 0.075’ 0.15’’ 0.036 0.025   Significant NHLBI 
 c.-7G>T 0.005  0.01    
rs36059701 p.Ala40Gly 0.22’’ 0.217’ 0.255’’ 0.32’’ 0.143 Significant NHLBI 
rs34165410 p.Gly116= 0.026 0.0167 0.04 0.036 0.04      
 p.Thr39= 0.005  0.01    
rs8670 c.*6C>T 0.29’’ 0.24 0.34’’ 0.286 0.2   Significant NHLBI 
rs1095 c.*68C>T 0.005 0.008  0.036 0.1171  
rs2229262 c.*70C>T 0.005  0.01  0.0191  
rs12532 c.*276A>G 0.3 0.31 0.28 0.286 0.24  
rs33929633 c.470-23delT 0.1     See below2 
AXIN2 
(NM_004655.3) 
CI002733 c.1994_1995insG 0.005 0.008 0.01 0.036  PCR artifact? 
rs35415678 p.Leu688= 0.016 0.008 0.03 0.036 0.04  
rs117688560 p.Ser762Asn 0.005 0.008   0.0014  
rs9906513 c.1907+39T>A  N/D 0.03 0.036 0.04 49TA samples 
rs186861426 c.-18G>A 0.12’’ 0.075’ 0.15’’ 0.036 0.025   Significant NHLBI 
rs36059701 p.Ala40Gly 0.22’’ 0.217’ 0.255’’ 0.32’’ 0.143 Significant NHLBI 
rs34165410 p.Gly116= 0.026 0.0167 0.04 0.036 0.04      
rs8670   c.*6C>T 0.29’’ 0.24 0.34’’ 0.286 0.2   Significant NHLBI 
rs1095 c.*68C>T 0.005 0.008  0.036 0.1171  
rs2229262   c.*70C>T 0.005  0.01  0.0191  
rs12532   c.*276A>G   0.3 0.31 0.28 0.286 0.24  
rs33929633 c.470-23delT 0.1     See below2 
BARX1 
(NM_021570.3) 
rs191789925 p.Ala48Thr 0.096   0.087 0.095 0.036 0.066  
rs12684081 c.600+30C>T 0.295 0.306 0.274 0.25 0.27  
rs149299341 c.600+50C>G 0.006 0.01   0.008  
rs11793856 p.Pro240= 0.26 0.25 0.276  0.267  
rs2297835 c.*17G>T 0.005 0.008   0.01  
rs59397123 c.*108G>A 0.06 0.05 0.06  0.092 Low cover 
BARX2 
(NM_003658.4) 
rs117979658 c.187+46G>T  0.017    Ov±TA only 
rs142822705 p.Ser64Pro 0.02 0.017 0.02  0.02  
rs149011396 p.Ile93= 0.005  0.01  0.0014       
rs10791010 c.574-5C>T  0.18  0.25 0.2 Ov±TA only3 
rs10791011 p.Pro203=  0.18  0.25 0.2 Ov±TA only3 
rs60183112 c.*128_*129insC  0.23  0.286 0.23 Ov±TA only3 
EDA 
(NM_001399.4) 
rs132630309 c.206G>T    0.036 0.011 Ov+TA  only 
rs2274469 c.526+27T>A    0.11 0.125 Ov+TA  only 
rs11426919 
c.527-34_527-
33insA 
   0.5  Artifact 
rs10579679 
c.706+12delTinsC
T 
   0.36  Ov+TA  only 
rs140058036 c.741+47G>C    0.07 0.06 Ov+TA  only 
rs62604271 c.741+125G>T    0.07  Ov+TA  only 
rs2296765 c.742-11C>T    0.25 0.37 Ov+TA  only 
rs201036606 c.*35C>G    0.036  Ov+TA  only 
OV±TA: All patients with ovarian disease (cancer and cysts) with or without tooth 
agenesis. TA±OV: All patients with tooth agenesis regardless of ovarian disease status. 
OV+TA: All patients with both ovarian disease and tooth agenesis. 1ethnically 
unmatched control; 2Homozygotes are not recognizable in the sequencing reaction;  
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Table 4-2 Continued. 
3rs10791010, rs10791011 and rs60183112 appear to be syntenic, the latter also as a 
separate polymorphism. ’=significant, ’’=highly significant difference compared to 
NHLBI Caucasian control population but not in comparison with the (smaller) control 
group described by Jezewski, et al. [supplement].  
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Table 4-3. Detailed analysis of significant allele frequency differences in all study 
groups. 
SEQUENCE VARIANT ALLELE FREQUENCY (MINOR ALLELE) 
REMARKS 
Gene rs# Location 
Total 
(n=95) 
OVnoTA 
(n=46) 
OV±TA 
(n=60) 
TA±OV 
(n=49) 
TAnoOV 
(n=35) 
OV+TA 
(n=14) 
Contr-
ol 
PAX9 rs12881240 p.H239= 0.30’ 0.25 0.24 0.31’ 0.36’’ 0.18 0.20 Significant 
MSX1 
rs186861426 c.-18G>A 0.12’’ 0.087’ 0.075’ 0.15’’ 0.2’’ 0.036 0.025   Significant 
rs36059701 p.Ala40Gly 0.22’’ 0.185 0.217’ 0.255’’ 0.23’ 0.32’’ 0.143 Significant 
rs8670   c.*6C>T 0.29’’ 0.23 0.24 0.34’’ 0.37’’ 0.286 0.2   Significant 
OVnoTA: All patients with ovarian disease only. OV±TA: All patients with ovarian 
disease with or without tooth agenesis. TA±OV: All patients with tooth agenesis 
regardless of ovarian disease status. TAnoOV: All patients with tooth agenesis, no 
ovarian disease. OV+TA: All patients with both ovarian disease and tooth agenesis. 
’=significant, ’’=highly significant when compared to the NHLBI Caucasian control 
population but not in comparison with the (smaller) control group described in Jezewski 
et al. [supplement]. Genotype frequency in the NHLBI Caucasian control population 
displayed Hardy-Weinberg Equilibrium for all Msx1 SNPs. The Pax9 SNP CAC>CAT 
deviated modestly from HWE probably due to its dependence on the adjacent SNP 
GCG>CCG, creating a potential CpG dinucleotide, which has a tendency to either alter 
the third position C of the CAC codon to a T or the first position G of the adjacent GCG 
to a C. rs36059701 and rs8670 are syntenic. NCBI reference sequences for PAX9 and 
MSX1 are NM_006194.3 and NM_002448.3, respectively. 
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Table 5-1. WNTA10 mutation allele frequencies.  
Source Ethnicity/ 
study group 
Number of detected 
alleles 
F228I allele 
frequency 
Our Tooth Agenesis (TA) 
study  
Caucasians 
with TA  
127 Phe and 33 IIle  0.206  
NCBI SNP data base  Caucasians  3348 Phe and 67 Ile 0.02  
NHLBI Exome Sequencing  
Project (ESP) 
Caucasians 8389 Phe and 209 Ile  0.024  
NHLBI Exome Sequencing  
Project (ESP) 
African 
Americans  
4370 Phe and 32 Ile  0.007  
Bohring et al. 2009 Am J 
Hum Genet 85: 97  
Caucasians 
without TA  
396 Phe and 2 Ile  0.005  
The WNT10A mutation Phe228Ile is unlikely to be a common polymorphism since its 
allele frequency is about 10 times higher in the tooth agenesis group than it is in several 
large control groups. 
 
